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ABSTRACT 
We designed and synthesized a series of chiral indolyarylsulfones (IASs) as new HIV-1 NNRTIs. The 
new IASs 8-37 showed potent inhibition of the HIV-1 WT NL4-3 strain and of the mutant K103N, 
Y181C, Y188L and K103N-Y181C HIV-1 strains. Six racemic mixtures, 8, 23-25, 31 and 33, were 
separated at semipreparative level into their pure enantiomers. The (R)-8 enantiomer bearing the chiral 
(-methylbenzyl) was superior to the (S)-counterpart. IAS derivatives bearing the (S) alanine unit, (S)-
23, (S,R)-25, (S)-31 and (S)-33, were remarkably more potent than the corresponding (R)-enantiomers. 
Compound 23 protected hippocampal neuronal cells from the excitotoxic insult, while efavirenz (EFV) 
did not contrast the neurotoxic effect of glutamate. The present results highlight the chiral IASs as new 
NNRTIs with improved resistance profile against the mutant HIV-1 strains and reduced neurotoxic 
effects. 
 
 
  
INTRODUCTION 
Human immunodeficiency virus type 1 (HIV-1) is the etiological agent of the acquired 
immunodeficiency syndrome (AIDS), a serious health problem which globally affects more than 30 
million people and caused about 1.1 million deaths in 2015.1 Approved antiretroviral medicines include 
drugs falling in five main classes which target different steps of the viral life cycle: reverse 
transcription (nucleoside reverse transcriptase inhibitors (NRTIs), which also include the nucleotide 
agents, and non-nucleoside reverse transcriptase inhibitors (NNRTIs)), viral maturation inhibitors 
(protease inhibitors), viral entry (fusion inhibitors and co-receptor antagonists), and integration 
(integrase inhibitors). Antiretroviral therapy (ART) for the treatment of AIDS/HIV infection combines 
antiretroviral drugs targeting different steps of the HIV life cycle. At present, standard first-line ART 
for adults consists of two NRTIs plus a non-nucleoside reverse-transcriptase NNRTI or an integrase 
inhibitor.2 The ART regimens have proven to control the HIV-1 replication and delay the progression 
of HIV infection, in particular in early stages of the disease. In most patients undergoing ART therapy 
the plasma viremia remains below the limit of detection for at least six months.3 However, drug 
resistance and cross resistance, adverse side effects and toxicity problems leading to fail compliance, 
still remain pending problems of ART regimens.4-6 Therefore, there is a considerable need for new anti-
HIV drugs that show better profile against the predominant mechanism of resistance and improved 
tolerability. 
Indolylarylsulfone (IAS) has proven to be a valuable scaffold for the design of potent HIV-1 
NNRTIs. IASs bearing the 3’,5’-dimethylphenylsulfonyl moiety at position 3 of the indole nucleus and 
different substituents (for example amino acid, hydroxyalkyl or Mannich base) at the indole-2-
carboxamide nitrogen, e.g. 1 (type A, Chart 1), displayed inhibitory activities against wild-type (WT) 
and drug-resistant HIV-1 in nanomolar range.7-11 
Efforts to overcome the problem of drug resistance led to the discovery of the second generation 
NNRTIs Etravirine (ETR) and Rilpivirine (RPV) which showed improved profile compared with the 
first generation NNRTIs.12 The presence of three aromatic rings allow ETR and RPV to adopt variable 
binding conformations, which are minimally affected by mutations of the amino acid residues into the 
allosteric binding site of the NNRTIs.13 Accordingly to this idea,13,14 introduction of the third aromatic 
nucleus to the parent IAS compound provided NNRTIs, e.g. 2  (type B, Chart 1), with broad activity 
against the WT HIV-1 and the mutant K103N and Y181C HIV-1 strains.15 
Asymmetric geometry of the HIV-1 non-nucleoside binding pocket, regiochemistry and 
stereochemistry of NNRTIs can dramatically influence their anti-HIV activity. Chiral HIV-1 NNRTIs 
are highly attractive since the enantiomers often show great differences of activity against the HIV-1 
WT and the drug resistant mutant strains (for example, see Ref.s16-19). The effect of chirality on the 
activity of HIV-1 NNRTIs have been recently reviewed.20 With respect to IAS, introduction of a 
methyl group at position  of the benzyl of 2 afforded (R)-3 and (S)-3 enantiomers (type B - chiral) 
which showed remarkably different activities against the K103N mutant HIV-1 strain: (R)-3, EC50 = 
4.3 nM; (S)-3, EC50 =128 nM (Table 3).21 On the contrary, the alanine enantiomers (R)-4 and (S)-4 
(type A - chiral) showed much lower (5 times) difference of activity.9 Replacement of the phenyl of 3 
with a pyridin-4-yl ring provided compound 5, with an even greater difference of activity.22 The (R)-5 
enantiomer proved to be highly potent against HIV-1 WT, EC50 = 0.2 nM, K103N, EC50 = 0.2 nM, and 
Y181C, EC50 = 2.1 nM (Table 3).22 Besides 5, introduction of the pyrimidin-4-yl ring (6) or furan-2-yl 
(7) rings also led to potent anti-HIV-1 agents.22 However, chemical modification of these substituents 
was not exhaustively explored. Herein, we designed and synthesized new IASs to explore structure-
affinity relationships (SARs) of chiral units at the nitrogen of the indole-2-carboxamide. In particular, 
we report new IAS derivatives 8-37, which exhibit potent anti-HIV-1 activity at low nano- and 
subnanomolar concentration (Chart 1 and Table 1). Contrary to previously reported results,9 we found 
that IAS derivatives bearing the (S)-alanine unit, 23, 25, 31 and 33 show high enantiospecific activity 
against HIV-1. 
 
 
Chart 1. Structure of New IASs 8−37 and Reference 
Compounds 1−7.a 
 
 
a8−37: see Table 1 for R substituent. 
 
Despite significant progress, nearly half of people with HIV develop primary neurological 
conditions during ART treatment in both developed and undeveloped countries. There is an unmet need 
of safer anti-HIV drugs for the long-term treatment of HIV infected people. The effect on damaged 
neurons of IAS 23, a representative member of the IAS NNRTI class, was assessed by administration 
to hippocampal neuronal cultures in the presence of 100 M glutamate as a neurotoxic stimulus. IAS 
23 showed higher protective effect than EFV from the excitotoxicity. 
 
 
CHEMISTRY 
Carboxamides 8-14, 18 and 19 were synthesized by coupling reaction of 5-chloro-3-((3,5-
dimethylphenyl)sulfonyl)-1H-indole-2-carboxylic acid (38)7 with the appropriate amine in the presence 
of benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP reagent) and 
triethylamine in anhydrous DMF at 25 °C for 12 h. Alternatively, 38 was transformed into the 
corresponding acid chloride with oxalyl chloride and pyridine in anhydrous dichloromethane at room 
temperature for 2 h, or into carboxylic acid imidazolide with 1,1′-carbonyldiimidazole in anhydrous 
THF at 25 °C for 2 h. Subsequent treatment of the activated acid with the appropriate amine provided 
the carboxamides 15-17. Compounds 20-37 were obtained under the same reaction conditions of 
carboxamides 8-14 and 17-19 starting from the corresponding acid 398 or 408 and the proper amine 
(Scheme 1).  
Separations of the (R,S) racemic mixtures 8, 23-25, 31 and 33 were performed by 
enantioselective HPLC using polysaccharide-based chiral stationary phases (CSPs) and an appropriate 
CSP/eluent system (see Experimental section). After optimization of the analytical methods, 
semipreparative enantioseparations were set-up to obtain the pure enantiomers at milligram scale for 
screening. The absolute configurations of the enantiomers of 8, 23, 24, 31, 33 and four stereoisomers of 
25 were empirically assigned by a combination of chemical correlation/enantioselective HPLC/circular 
dichroism methods. Commercially available (S)-enantiomers of the amines were used as starting 
material for the stereospecific synthesis of the (S) forms. The enantiomeric excess of each enantiomer 
separated from the racemic mixtures 8, 23-25, 31 and 33 was determined by HPLC (Figures 5S-10S of 
Supporting Information). 
 
 
Scheme 1. Synthesis of compounds 8-37.a 
 
aReagents and reaction conditions: (a) amine, PyBOP 
reagent, triethylamine, anhydrous DMF, 25 °C, 12 h, 35-
98%; (b) (i) pyridine, oxalyl chloride, dichloromethane, 
25 °C, 2 h, (ii) amine, 25 °C, 12 h, 7-11%; (c) (i) 1,1′-
carbonyldiimidazole, anhydrous THF, 25 °C, 2 h, (ii) 3-
(aminomethyl)aniline, 25 °C, 2 h, 71%. 
 
 
 
 
RESULTS AND DISCUSSION 
 Anti-HIV-1 activity. The effective concentrations (EC50 values, nM) to inhibit by 50% the HIV-
1 WT (NL4-3 strain) in MT-4 cells (MTT method), and cytotoxic concentrations (CC50 values, nM) to 
induce 50% death of non-infected cells of IASs 8-37 are shown in Table 1. Except compounds 10 
(EC50 = 132.7 nM) and 26 (EC50 = 3.8 nM), all new IASs showed EC50 values at subnanomolar 
concentration, which were below the limit of detection of the assay. Compounds 8-15, 17, 19-22, 24-26, 
28 and 30-36 displayed CC50 values >20000 nM, and 23, 29 and 37 were in the 10000-20000 nM range. 
Several IASs showed selectivity indexes (SI = CC50/EC50 ratio) >50000, three derivatives, 22, 23 and 
28, SI>100000. IAS 22 showed the highest SI value (SI > 244620) within the series. The SI values 
were clearly superior to NVP, EFV, and ETR and comparable to the reference IASs 2-7.  
 We initially synthesized IAS derivative 8-14 bearing different benzyl groups at the indole-2-
carboxamide nitrogen. Introduction of a fluorine atom at position 2 of the phenyl group gave compound 
8 that was as potent as 3 against the NL4-3 HIV-1 WT and superior to 3, NVP and EFV against the 
mutant K103N (EC50 = 0.7 nM) and Y181C (EC50 = 103 nM)  HIV-1 strains (Table 2). However, these 
values were slightly superior to those of compound 2.15 We separated at the semipreparative level the 
racemic mixture 8 into the pure enantiomers (S)-8 and (R)-8 by enantioselective HPLC on 
polysaccharide-based chiral stationary phases (CSPs). The (S)-8 and (R)-8 enantiomers proved to be 
equipotent (EC50 = 0.7 nM) against the NL4-3 HIV-1 WT strain and showed similar cytotoxicity 
(Table 3). Most importantly, the enantiomer (R)-8 demonstrated potent antiretroviral activity against 
the mutant K103N and Y181C HIV-1 strains (EC50 = 0.7 nM) in the cellular assay, being 147-fold 
(K103N) and 871-fold (Y181C), respectively, more potent than (S)-8. Against the K103N and Y181C 
resistant mutants, (R)-8 was more potent than reference drugs NVP, EFV and ETR. Also against 
recombinant HIV-1 RT carrying the K103N and Y181C mutations, (R)-8 was several-fold more potent 
than (S)-8 (Table 4). 
 Introduction of a methyl group at the methylene of IAS 7 gave 9 which except the Y181C  
(EC50 = 22 nM), showed modest inhibition of the mutant K103N, Y188L and K130N-Y181C HIV-1 
strains (Table 2). The potent antiretroviral activity showed by 8 prompted the synthesis of fluoro-
containing IAS derivatives 12-14. Introduction of a fluorine atom at the -methyl group of 3 afforded 
IAS 13, a racemate that was superior to 3 against the K103N (EC50 = 0.7 nM) and Y181C (EC50 = 82 
nM) HIV-1 resistance mutations, but did not inhibit the double mutant K130N-Y181C HIV-1 strain 
(Table 2). The 2,3-difluoro-IAS 14 proved to be potent inhibitor of the NL4-3 HIV-1 WT, and the 
mutant K103N (EC50 = 0.7 nM) and Y181C (EC50 = 2.0 nM) strains, but was ineffective against the 
double mutant K103N-Y181C strain (Table 2). 
IASs  15 and 16 were designed as constrained analogues of 5 and 6, where the nitrogen of the 
cyano group mimicked the nitrogen at position 1 of the pyridine/pyrimidine ring. Compound 15 proved 
to be a strong inhibitor of the K103N (EC50 = 0.6 nM) and Y181C (EC50 = 2.2 nM) HIV-1 mutations, 
but was unable to inhibit the double mutant K130N-Y181C strain. Extrusion of the basic nitrogen atom 
from the pyridinyl ring led to 17 and the structurally related derivatives 18 and 19. The 3-aminobenzyl 
derivative 17 uniformly inhibited all HIV-1 strains: NL4-3 WT, K103N and Y181C, EC50 = 0.7 nM; 
Y188L, EC50 = 24 nM and K103N-Y181C, EC50 = 86 nM. Incorporation of the 3-amino group into a 2-
aminoimidazolyl moiety (compound 18) caused considerable decrease of activity against all viral 
strains and recombinant HIV-1 RT (Table 2 and Table 5). On the contrary, the indazol-3-yl derivative 
19 inhibited the NL4-3 HIV-1 WT and the mutant K103N and Y181C strains with EC50 = 0.6 nM, and 
showed significant inhibition of the Y188L and K103N-Y181C strains with EC50 of 142 nM and 548 
nM, respectively (Table 2). 
 
  
Table 1. Anti-HIV-1 Activity of IASs 8-37, Reference Compounds 2, 3, 5-7, and NVP, EFV, 
ETR and AZT against HIV-1 NL4-3 Strain.a,b 
 
 
 
  
 HIV-1 NL4-3  
compd R CC50
b
 
(nM) 
EC50c ± SD 
(nM) SI
d
 
8f 
 
>51545 0.7e >73642 
9f 
 
>54711 0.7e >78159 
10f 
 
>47397 132.7 ± 12 >359 
11 
 
>49903 0.6e >83172 
12f 
 
>49706 0.6e >82842 
13f 
 
49178 ± 4103 0.7e >70255 
14 
 
>51132 0.7e >73046 
15 
 
>53773 0.6e >89621 
16 
 
6840 ± 1420 0.7e >9771 
17 
 
>53422 0.7e >76317 
18 
 
5886 ± 335 0.6e >9810 
19 
 
>50711 ± 0 0.6e >84518 
20f 
 
29387 ± 8 0.6e >48978 
21f 
 
21745 ± 5626  0.6e >36856 
22 
 
>48924 0.2e >244620 
23f 
 
19465 0.2e 102452 
24f 
 
47045 ± 762 0.6e >78408 
25f 
 
21890 ± 557  0.6e >36483 
26 
 
35730 3.8 ± 2.1 9478 
27f 
 
9502 0.2 e 52789 
28 
 
24466 0.2e 143922 
29f 
 
16012 0.2e 94188 
30 
 
>48830 0.6e >81383 
31f 
 
28068 ± 2083 0.6e >46780 
32 
 
>50043 0.6e >83405 
33f 
 
24241 ± 9687  0.6e >40402 
34 
 
>47349 0.6e >78916 
35f 
 
23265 ± 7343 0.6e 23265 
36f 
 
23007 ± 4908 0.6e >38345 
37f 
 
15232 ± 199  0.6e >25387 
2g 
 
37994 ± 12164 0.2e 172700 
3f,h 
 
>53535 0.6e >205903 
5f,i 
 
30216 ± 2308 0.2 ± 0.2 151078 
6i 
 
>54953 0.22e >249786 
7i 
 
>56433 0.2 ± 0.1 >282218 
NVPj — >18776 112.4 ± 74.9 >167 
EFVk — >15839 15.9 ± 12.7 >996 
ETRl — >22973 16.1 ± 14.2 >1426 
AZTm — >30595 3.7 ± 3.7 >8269 
aData are mean values of two to three independent experiments each one in triplicate. bCC50: cytotoxic 
concentration (nM) to induce 50% death of noninfected cells, as evaluated with the MTT method in MT-4 
cells. cEC50 (HIV-1 NL4−3): effective concentration (nM) to inhibit by 50% HIV-1 (NL4−3 strain) 
induced cell death, as evaluated with the MTT method in MT-4 cells. dSI: selectivity index calculated as 
CC50/EC50 ratio. eLowest detectable nM concentration. fData of the racemic mixture. gLit.15 hLit.16 iLit.22 
jNVP, nevirapine. kEFV, Efavirenz. lETR, etravirine. mAZT, azidothymidine. 
 
  
NN
We synthesized IASs 20-25 by coupling a type A unit, the amino acid glycine (1) or alanine (4), 
with a type B unit, the benzyl of 2, the -methylbenzyl of 3 or the 1-(pyridin-4-yl)ethyl group of 5. All 
compounds strongly inhibited the WT NL4-3 HIV-1 strain. Racemic compounds 21, 23 and 25, bearing 
the alanine unit inhibited the mutant K103N HIV-1 strain at nanomolar concentrations with EC50 
values of 1.9, 1.9 and 7.4 nM, respectively (Table 2). On the other hand, compound 22 and racemates 
23 and 24 bearing the (pyridin-4-yl) group as a terminal tail showed potent inhibition of the mutant 
Y181C HIV-1 strain with EC50 values of 20, 21 and 0.6 nM, respectively. Compound 23 and 24 
inhibited the mutant K103N-Y181C and Y188L HIV-1 strains with of EC50 = 838 nM and EC50 = 610 
nM, respectively.  
 The racemic mixtures 23 and 24 were resolved at the semipreparative level by enantioselective 
HPLC into the corresponding pure enantiomers (R)-23, (S)-23, and (R)-24, (S)-24; the diastereomeric 
mixture 25 was separated into the four stereoisomers (R,S)-25, (S,R)-25, (R,R)-25 and (S,S)-25 (Table 
3). Enantiomers (R)-23 and (S)-23 proved to be equipotent (EC50 = 0.7 nM) against the NL4-3 HIV-1 
WT; however, (S)-23 was remarkably superior to (R)-23 against the mutant K103N (EC50 = 0.7 nM, 
162-fold), Y181C (EC50 = 0.7 nM, 258-fold), Y188L (EC50 = 666 nM, >35-fold) and K103N-Y181C 
(EC50 = 857 nM, 8-fold) HIV-1 strains. Similar results were obtained against the corresponding 
mutated HIV-1 RT enzymes (Table 4). Enantiomers (R)-24 and (S)-24 showed small differences of 
activity against all HIV-1 mutants. IAS derivatives (R,S)-25 and (S,R)-25 showed significant 
differences: (S,R)-25 was 3-fold (WT, EC50 = 0.6 nM), 340-fold (K103N, EC50 = 0.6 nM), 1113-fold 
(Y181C, EC50 = 0.6 nM), 38-fold (Y188L, EC50 = 742 nM) and 15-fold (K103N−Y181C, EC50 = 1261 
nM), respectively, more potent than (R,S)-25 in the cellular assay; (S,S)-25 was superior to (R,R)-25 
against the NL4-3 WT (EC50 = 0.6 nM, 6-fold), K103N (EC50 = 1.3 nM, 927-fold), Y181C (EC50 = 0.6 
nM, 1948-fold), Y188L (EC50 = 612 nM, 44-fold) and K103N-Y181C (EC50 = 1280 nM, 21-fold). The 
cellular activity of the enantiomers 25 correlated with the enzymatic data (Table 4). 
 Table 2. Activity of Compounds 8-37, Reference Compounds 2, 3, 5-7, and NVP, 
EFV, ETR and AZT against Mutant HIV-1 Strains.a,b 
 EC50 (nM) 
compd K103N Y181C Y188L K103N-Y181C 
8f 0.7
c
 
1d 
103 ± 6 
>147 
969 ± 680 
>1384 
3959 ± 1253  
>5656 
9f 109 ± 22 155 
22 ± 4.4 
31 
350 ± 160 
500 
12037 ± 11489 
17195 
10f nde nd nd nd 
11 0.6 1 
399 ± 39 
665 nd 
27746 ± 31339 
46243 
12f 1.2 ± 0.8 2 
716 ± 179 
1198 nd 
>49706 
>82843 
13f 0.7 1 
82 ± 62 
117 nd 
27321 ± 34270 
39030 
14 0.7 1 
2.0 ± 2.0 
2.9 nd 
>51132 
>73046 
15 0.6 1 
2.2 ± 0.7 
3.7 nd 
>53773 
>89622 
16 0.7 1 
65 ± 22 
92 nd 
>6840 
>9771 
17 0.7 1 
0.7 
1 
24 ± 8.7 
34 
86 ± 107 
123 
18 18 ± 20 30  
79 ± 59 
132 nd 
>5886 
>9810 
19 0.6 1 
0.6 
1 
142 ± 101 
237 
548 ± 12 
913 
20f 210 ± 19 350 
76 ± 76 
127 
1622 ± 1278 
2703 
>29387 
>48978 
21f 1.9 ± 3.7 3.2 
167 ± 67 
283 
3792 ± 780 
6427 
24868 ± 6440 
42149 
22 190 ± 12 316 
20 ± 6 
100 
1401 ± 72 
700 
6086 ± 206 
30430 
23f 1.9 ± 0.2 52 
21 ± 8 
105 
819 ± 221 
4095 
838 ± 21 
4190 
24f 38 ± 19 64 
0.6 
1 
610 ± 38 
1017 
13333 ± 13752 
22227 
25f 7.4 ± 0.4 12 
167 ± 74 
278 
12893 ± 13226 
21488 
>36483 
>60805 
26 1340 ± 652
 
352 
321 ± 112 
84 
>3576 
>941 
>3576 
>941 
27f 18 ± 0.9
 
30 
129 ± 54 
215 
>9802 
>16336 
>9802 
>16336 
28 279 ± 124
 
1395 
17 ± 11 
85 
2321 ± 815 
11605 
4677 ± 2012 
23285 
29f 170 ± 115
 
850 
170 ± 84 
850 
4770 ± 2118 
23850 
5281 ± 2021 
26405 
30 19.6 ± 19.6 33 
0.6 
1 
449 ± 27 
>743 
2305 ± 2500 
>3842 
31f 0.6 1 
0.6 
1 
760 ± 95 
>1267 
798 ± 456 
>1330 
32 60 ± 80 
>86  
<0.6 
nd 
1120 ± 500 
>1600 
18534 ± 21570 
>26477 
33f 1.9 ± 1 3 
27 ± 3.9 
45 
2432 ± 972 
4053 
4513 ± 2015 
>7521 
34 1326 ± 1288 1894 
1.3 ± 1.5 
1.9 
6155 ± 3863 
10258 
>47349 
>72248 
35f 26 ± 1.9 43 
93 ± 56 
155 
4240 ± 2015 
7067 
>23265 
>38775 
36f 387 ± 239 552 
13 ± 7.4 
19 
3671 ± 110 
6118 
>23007 
>38345 
37f 36 ± 36 6 
108 ± 77 
180 
>15232 
>25387 
6474 ± 3156 
10790 
2g 0.9 ± 0.4 4 
18 ± 7.0 
80 
90 ± 83 
409 
1921 ± 2050 
8691 
3f,h 33 ± 6.4 55 
720 ± 690 
1200 nd 
 3267 ± SD 
5445 
5f,i 9.4 ± 2.3 47 
87 ± 75 
435 nd 
1111 ± 940 
5555 
6i 0.22
d
 
1 
2.20 ± 1.3 
10 
50.6 ± 21.9 
257 
132 ± 153 
600 
7i 0.2
d
 
1 
0.8 ± 0.2 
4 
45 ± 0.23 
225 
971 ± 474 
4855 
NVP >3756 
>33 
>3756 
>33 
>3756 
>33 
>3756 
>33 
EFV 130 ± 180 8.2 
160 ± 180 
10 
760 ± 630 
48 
>317 
>20 
ETR 0.7 ± 0.4 0.04 
18 ± 14 
1.1 
16 ± 9 
1 
4.6 ± 2 
0.2 
AZT 16 ± 12 4.3 
6.0 ± 3.4 
1.6 
33 ± 18 
8.9 
16 ± 13 
1.0 
aData are mean values of two to three independent experiments each one in triplicate. bEC50: 
effective concentration (nM) to inhibit by 50% cell death induced by the indicated mutant HIV-
1 strain, as evaluated with the MTT method in MT-4 cells. cLowest detectable nM 
concentration. dFC: fold change obtained as ratio between EC50s of the indicated drug resistant 
mutant HIV-1 strain and HIV-1 WT NL4-3 strain. end: no data. fData of the racemic mixture. 
gLit.15 hLit.16 iLit.22 
 
 
 
 
 In the cellular assay, the (R)-enantiomer of IAS derivatives bearing a single type B unit was 
superior to the (S)-counterpart (compare (R)-8 with (S)-8, (R)-3 with (S)-3,21 and (R)-5 with (S)-522) 
(Table 3). In previous studies, the chirality of the alanine only weakly affected the antiretroviral 
activity (e.g.: 4: single type A unit).9 On the contrary, coupling of alanine with pyridin-4-
ylmethanamine (type A+B, chiral) resulted in high stereospecific activity: (S)-23 was superior to the 
corresponding (R)-enantiomer, and (S,R)-25 and (S,S)-25 were superior to the corresponding (R,S)-25 
and (R,R)-25 enantiomers. To confirm these observations, we separated racemates 31 and 33 having the 
chiral alanine. As inhibitors of the HIV-1, the (S) enantiomers of these chiral derivatives, (S)-31 and 
(S)-33, proved to be more potent than their (R) counterparts (Table 3). 
 
 
 
 
  
Table 3. Anti-HIV-1 Activity of Racemates 8, 23-25, 31, 33, Reference Compounds 3, 5, and the 
corresponding Enantiomers against Mutant HIV-1 Strains.a,b 
  EC50 (nM) 
compd WT K103N Y181C Y188L K103N-Y181C 
8g 0.7c 0.7c 103 ± 6 969 ± 680 3959 ± 1253  
(R)-8 0.7c 0.7c 0.7c 165 ± 21 2486 ± 2743 
(S)-8 0.7c 103 ± 8 680 ± 432 >51551 >51551 
23g 0.2c 1.9 ± 0.6 21 ± 9 819 ± 315 838 ± 215 
(R)-23 0.7c 114 ± 4 181 ± 38 >23104 7123 ± 2324 
(S)-23 0.7c 0.7c 0.7c 666 ± 38 857 ± 723 
24g 0.6c 305 ± 95 11.2 ± 4 610 ± 38 13333 ± 13752 
(S)-24 0.7c 438 ± 229 2.5 ± 3 3048 ± 114 4628 ± 1581 
(R)-24 0.7c 152 ± 38 5.71 ± 2 3272 ± 818 12246 ± 171 
25g 0.6c 7.4 ± 0.4 167 ± 74 12893 ± 13226 >364 
(R,S)-25 1.9 ± 0.4 204 ± 37 668 ± 37 >28532 19348 ± 14246 
(S,R)-25 0.6c 0.6c 0.6c 742 ± 260 1261 ± 612 
(S,S)-25 0.6c 1.3 ± 1.1 0.6c 612 ± 202 1280 ± 556 
(R,R)-25 3.8 ± 0.2 1206 ± 111 1169 ± 779 >27010 >27010 
31g 0.6c 0.6c 0.6 c 760 ± 95 798 ± 456 
(R)-31 0.6c 76 ± 76 171 ± 57 5738 ± 1748 >24543 
(S)-31 0.6c 0.6c 0.6c 380 ± 128 779 ± 532 
33g 0.6c 1.9 ± 1 27 ± 3.9 2432 ± 972 4513 ± 2115 
(R)-33 0.6c 311 ± 123 933 ± 369 >30195 >30195 
(S)-33 0.6c 0.6c 3.5 ± 3.9 700 ± 175 1886 ± 715 
3e,g 0.6c 33 ± 6.4 720 ± 690 ndd  3267 ± SD 
(R)-3e 
 
2.1 ± 1.9 
 
4.3 ± 3.2 86 ± 43 193 ± 64 nd 
(S)-3e 6.3 ± 4.2 128 ± 107 3469 ± 1735 >36404 nd 
5f,g 0.2c 9.4 ± 2.3 87 ± 75 nd 1111 ± 453 
(R)-5f 0.2c 0.2c 2.1 ± 1.5 933 ± 2.3 150 ± 17 
(S)-5f 0.2c 4.3 ± 1.7 128 ± 11 5169 ± 3160 4124 ± 913 
NVP 112.4 ± 74.9 >3756 >3756 >3756 >3756 
EFV 15.9 ± 12.7 130 ± 180 160 ± 180 760 ± 630 >317 
ETR 16.1 ± 14.2 0.7 ± 0.4 18 ± 14 16 ± 9 4.6 ± 2 
AZT 3.7 ± 3.7 16 ± 12 6.0 ± 3.4 33 ± 18 16 ± 13 
aData are mean values of two to three independent experiments each one in triplicate. bEC50: effective 
concentration (nM) to inhibit by 50% cell death induced by the indicated mutant HIV-1 strain, as evaluated with 
the MTT method in MT-4 cells. cLowest detectable nM concentration. dnd, not done. eLit.21 fLit.22 gData of the 
racemic mixture. 
 
 
 
Table 4. Anti-HIV-1 Activity of pure Enantiomers of 8, 23, 25, 31, 33, and NVP, 
EFV and ETR against the WT RT, K103N, Y181I and K103N-Y181C Mutant RTs.a 
 IC50 (nM)b 
compd WT K103N Y181I K103N-Y181C 
(R)-8 87 ± 7 228 ± 21 456 ± 52 222 ± 19 
(S)-8 175 ± 11 ndc 17220 ± 1214 >10000 
(R)-23 13010 ± 3000 >50000 60980 ± 3214 >200000 
(S)-23 506 ± 74 417 ± 64 870 ± 52 >40000 
(R,S)-25 1190 ± 74 3550 ± 780 9510 ± 1123 8420 ± 950 
(S,R)-25 610 ± 85 300 ± 67 1700 ± 112 490 ± 88 
(S,S)-25 430 ± 28 2590 ± 800 440 ± 61 860 ± 120 
(R,R)-25 410 ± 52 23700 ± 5000 5790 ± 622 13800 ± 1900 
(R)-31 1800 ± 250 19910 ± 380 3350 ± 262 nd 
(S)-31 470 ± 63 2860 ± 420 3140 ± 168 14280 ± 2000 
(R)-33 145 ± 25 70 ± 9 276 ± 18 233 ± 33 
(S)-33 113 ± 11 1120 ± 250 14210 ± 915 9640 ± 1200 
NVP 400 ± 36 7000 ± 690 >20000 nd 
EFV 80 ± 7 >20000 400 ± 22 nd 
ETR 10 ± 0.5 20 ± 3 164 ± 15 97 ± 11 
aData are the mean values of at least three separate experiments. bCompound concentration (IC50, 
nM) required to inhibit the RT activity of the indicated strain by 50%. cnd: no data.  
 
 Table 5. Anti-HIV-1 Activity of Compounds 16-18, 30, 32, and NVP, EFV and 
ETR against the WT RT, K103N, Y181I and K103N-Y181C Mutant RTs.a 
 IC50 (nM)b 
compd WT K103N Y181I K103N-Y181C 
16 23 ± 3 72 ± 11 306 ± 49 514 ± 102 
17 41 ± 7 66 ± 11 64 ± 10 35 ± 5 
18 278 ± 44 183 ± 27 284 ± 49 470 ± 70 
30 202 ± 37 548 ± 93 529 ± 99 835 ± 110 
32 145 ± 20 538 ± 93 461 ± 461 586 ± 85 
NVP 400 ± 36 7000 ± 690 >20000 ndc 
EFV 80 ± 7 >20000 400 ± 22 nd 
ETR 10 ± 0.5 20 ± 3 164 ± 15 97 ± 11 
aData are the mean values of at least three separate experiments. bCompound concentration 
(IC50, nM) required to inhibit the RT activity of the indicated strain by 50%. cnd: no data.  
 
 
 
The inhibitory concentrations (IC50 values, nM) to inhibit by 50% the HIV-1 WT RT and the 
K103N, Y181I and K103N-Y181C mutated RTs are depicted in Tables 4 and 5. Among the tested 
compounds, eutomers, (R)-8, (S)-23, (S,R)-25, (S,S)-25 (except Y181I), (R)-33, and compounds 16-18 
inhibited the HIV-1 WT RT and the K103N and Y181C mutated RTs with IC50 values at high 
nanomolar concentration. Compounds (R)-8, 16-18, (S,R)-25, (S,S)-25, 30, 32 and (R)-33 inhibited the 
HIV-1 K103N-Y181C mutated RT in the same range of concentration. In general, antiviral data in cell 
cultures correlated with inhibitory enzymes data. Enantiomers with the highest inhibition of HIV-1 WT 
and mutant strains in MT-4 cells showed the best inhibition of HIV-1 WT and mutated RTs (compare 
cellular and enzymatic data of (R)-8 with (S)-8, (R)-23 with (S)-23, (R,S)-25 with (S,R)-25, (R,R)-25 
and (S,S)-25, (R)-31 with (S)-31. (Tables 1-5). In MT-4 cells, compound (R)-8 inhibited the HIV-1 WT 
and the K103N and Y181C mutant strains with EC50 of 0.7 nM (Tables 1 and 2), and the corresponding 
RTs with IC50s of 87, 228 and 456 nM (Table 4), respectively. Compound 17 showed the same EC50 
values against HIV-1 WT, K103N and Y181C strains in MT-4 cells (Tables 1 and 2), and inhibited the 
corresponding RTs with IC50s of 41, 66 and 64 nM, respectively (Table 5). Interestingly, in MT-4 cells, 
17 potently inhibited the HIV-1 K103N-Y181C double mutant with EC50 of 86 nM (Table 2) and the 
corresponding RT with IC50 of 35 nM (Table 5). IAS derivative (S,R)-25 inhibited the HIV-1 WT and 
the K103N and Y181C mutant strains with EC50s of 0.6 nM, and the HIV-1 K103N-Y181C with EC50 
of 1261 nM (Table 3). For comparison, (R,S)-25 showed notably higher inhibitory concentrations in 
both cellular and enzymatic assays.  
 
 Molecular modeling. The binding mode of the reported compounds was evaluated by a series 
of molecular docking simulations using a previously reported procedure.13 The docking results showed 
consistent binding modes in the HIV-1 WT RT as well as in the mutated K103N, Y181C and K103N-
Y181C RTs. The key interactions observed are: (i) a H-bond between the indole NH and the K101 
carbonyl oxygen; (ii) the chlorine atom fitted into a hydrophobic cavity near V106 and L234; (iii) the 
3,5-dimethylphenyl moiety placed in the aromatic cleft formed by the side chains of Y181, Y188, and 
W229; (iv) a series of hydrophobic interactions between the linker and the heteroaryl moieties with the 
side chains of V179 and E138:B. The reported binding mode, in accordance with the biological data, 
was consistent between the enantiomeric couples. The binding modes of derivatives (R)-8 and (S)-8 
proposed by PLANTS are shown in Figure 1.   
  
    
    
Figure 1. PLANTS proposed binding modes for derivatives (R)-8 (yellow) and (S)-8 (blue) into the non-nucleoside binding 
site of the RT: top left panel, WT (cyan); top right panel, K103N (magenta); bottom left panel, Y181C (orange); bottom 
right panel, K103N-Y181C (pink). Residues involved in interactions are reported as lines. Mutated residues are depicted as 
stick. RTs are shown as cartoon. H-bonds are depicted as yellow dotted lines.   
 
 
 
 
    
Figure 2. Trajectories snapshots versus the Y181C RT: left panel, (S)-8 (magenta); right panel, (R)-8 (cyan). Residues 
involved in interactions are reported as lines. Mutated residue is depicted as stick. RT is shown as cartoon. H-bonds are 
depicted as yellow dotted lines. 
 
Interestingly, the biological results showed specific correlation between the linker length and 
the configuration of the asymmetric center: the most active enantiomer of IASs bearing the short linker 
(chiral type B) unit was generally in the (R) configuration, while the (S) enantiomer was superior in the 
longer linker (chiral type A unit) series. To gain further insight of the different behavior of the various 
enantiomers, we carried out a series of molecular dynamic simulations of two representative pairs of 
derivatives: (R)-8, (S)-8 (short linker) and (R)-23, (S)-23 (long linker). We used the Y181C mutated RT 
in the simulations because of the greatest differences of IC50 values within the enantiomeric pairs.  
In comparing the trajectories of the (R)-8 and (S)-8/Y181C RT complexes, the breakage of  the 
interaction between the dimethylphenyl moiety of (R)-8 and Y181 was compensated by the new 
interaction between the fluorinated aromatic ring and the C181 residue.23 (Figure 2). Furthermore, the 
asymmetric methyl group was positioned into a hydrophobic cleft located toward the inner part of the 
binding pocket formed by V179, C181 and Y188 residues. With (S)-8, the methyl moved far from 
above indicated hydrophobic residues and thus failed these key interactions. The other contacts 
observed in the docking studies were retained during the whole simulations by both enantiomers 
(Figure 2). 
    
Figure 3. Trajectories snapshots versus K103N RT: left panel, (S)-23 (white); right panel, (R)-23 (pink). Residues involved 
in interactions are reported as lines. Mutated residue is depicted as stick. RT is shown as cartoon. H-bonds are depicted as 
yellow dotted lines. 
 
 
 
 A similar behavior was observed in the trajectories of (R)-23 and (S)-23/Y181C RT complexes. 
The (S) asymmetric methyl group laid in the V179, C181 and Y188 cleft forming hydrophobic contacts, 
while the (R) methyl did not. For both (R)-23 and (S)-23 enantiomers the dimethylphenyl group was 
stabilized by interaction with C181 and the pyridine ring, due to the longer linker, formed contact with 
E138:B (Figure 3). 
 The simulations confirmed the crucial role of the linker. Indeed, the enantiomer with the best 
antiviral activity shifted from (R) to (S) moving from short to long linker because of its best fitting at 
the binding site. (Figure 1S, Supporting Information). The correlation between the calculated binding 
free energy for four compounds with the experimental IC50 (r2 of 0.75) supports the proposed structural 
binding model (Table 6). 
 
 
Table 6. Experimental IC50 versus computed binding free energy. 
Comp Exp. Y181C IC50 Calc. G 
(R)-8 0.456 -9.876 
(S)-8 17.22 -9.279 
(R)-23 60.98 -9.135 
(S)-23 0.87 -9.731 
 
  
 Neurotoxicity studies. ART has significantly increased life expectancy of HIV infected 
people.24 However, neurological problems emerge in approximately 50% of HIV patients.25 The 
neurocognitive damage often accelerates during the clinical treatment of the AIDS/HIV infection,26 and 
remains even after suppression of the peripheral viral infection.27 Neuronal injury during the 
antiretroviral therapy may arise from unknown mechanisms through toxins, pro-inflammatory 
cytokines, reactive oxygen species (ROS) and nitric oxide (NO) released by activated glial cells in 
response to residual viral replication.28  
 Activation of microglia, the brain’s resident macrophages, has been extensively reported as one 
of the most important contributors of HIV-related neuroinflammation,29 and in some case the 
antiretroviral therapy is able to revert this activation.30 To verify whether IAS derivatives could 
interfere with the inflammatory status of microglia, BV2 cells were treated with lipopolysaccharide 
(LPS) (50 ng/mL), a pro-inflammatory stimulus that is elevated in the blood of HIV+ individuals,31 in 
presence or absence of different doses of compound 23, one of most potent HIV-1 NNRTI of the series, 
and the amount of NO released by the cells was measured, EFV was used as reference compound. Data 
showed that both 23 and EFV treatments were able to reduce LPS-induced NO release at 1 μM and 10 
μM concentrations (Figure 2S, Supporting Information). 
 The pro-inflammatory or anti-inflammatory profile of BV2 cells treated with 23 or EFV was  
analyzed as expression of M1 (pro-inflammatory) and M2 (anti-inflammatory) mRNAs. Compounds 23 
and EFV differently decreased the expression of CD86 and iNOS M1 genes. As shown in Figure 4, 
both iNOS and CD86 were significantly reduced by 23, while only iNOS was reduced by EFV 
treatment. These treatments did not alter the expression of the anti-inflammatory genes CD163 and 
Fizz. 
 
  
      
     
Figure 4. 23 reduced the pro inflammatory M1-related genes on BV2 cells. BV2 cells were treated with 103 nM (R,S)-23 or 
EFV. mRNA expression of M1 (iNOS and CD86) and M2 (CD163 and FIZZ) related genes was assayed by RT-PCR. Data 
are expressed as fold increase vs ctl. N=4; *p<0,05 and **p<0,001 vs ctrl by Student’s t-test. 
 
 
 To exclude the possibility that the effects could be due to a different rate of cell proliferation, 
BV2 microglial cells were cultured in presence of 23 or EFV at different doses (10 nM, 102 nM, 103 
nM and 104 nM) and the proliferation rate of these cells was evaluated. Data show that the treatments 
did not alter the BV2 cell proliferation at any doses (Figure 3S, Supporting Information). 
 HIV-mediated microglia activation is responsible of release of neurotoxic factors such as 
excitatory molecules32 and inflammatory cytokines,33 resulting in neuronal dysfunction and cell death. 
To verify the effect on damaged neurons, compound 23 was administrated to hippocampal neuronal 
cultures in the presence of 100 M glutamate as a neurotoxic stimulus. The compound proved to 
protect neurons from the excitotoxic insult. Notably, EFV was not efficacious to contrast the neurotoxic 
effect of glutamate (Figure 5). 
 
 
Figure 5. 23 treatment protect neurons against glutamate excitotoxicity. Neuronal cultures were stimulated with 100 M 
glutamate in presence or absence of 103 nM 23 or EFV. Data are expressed as number of cell/optical field. N=3, *p<0,05 vs 
CTL by Kruskal-Wallis One Way Analysis of Variance (Dunn’s method). 
 
In Silico Prediction of Physicochemical Properties. The physicochemical properties of 
compounds 8, 23 and 25 assessed by SwissADME34 and QikProp35 programs are shown in Table 7. 
The predicted physicochemical properties of derivatives 9-22, 24 and 26-37 are reported in Table 1S, 
Supporting Information. Compounds 8, 23 and 25 matched Lipinski's rule of five,36 namely logP <5, H-
bond donors ≤5, H-bond acceptors ≤10 and a molecular weight <500.36 Derivative 8 did not show 
violation of Lipinski's rule of five (Rule of five = 4), while derivatives 23 and 25 showed one violation 
(molecular weight >500; Rule of five = 3). Compounds 8, 23 and 25 exhibited significant values in the 
topological polar surface area (TPSA),37 apparent Caco-2 and madin-carby canine kidney (MDCK) 
cells permeability predictions. These results show that compounds 8, 23 and 25  have the potential to 
diffuse across membranes. 
Table 7. In silico physicochemical properties of 8, 23 and 25. 
Cmpd LogPa H-bond Acc.b 
H-bond 
Don.c MW
d
 TPSAe QPP Cacof QPP MDCKg 
8 4.26 4 2 484.97 87.41 1595.51 3021.29 
23 2.03 5 3 525.03 129.40 202.03 333.34 
25 2.22 5 3 539.06 129.40 286.71 457.122 
Physicochemical properties predicted by SwissADME:34 aOctanol-water partition coefficient predictor by 
topological method implemented from Moriguchi;38,39 bNumber of H-bond acceptors; cNumber of H-bond 
donors; dMolecular Weight; eMolecular polar surface area: this parameter correlates with human intestinal 
absorption (<140).37 Physicochemical properties predicted by QikProp: fQPP Caco - Apparent Caco-2 
permeability (nm/sec) (<25 poor, >500 great); gQPP MDCK - Apparent MDCK permeability (nm/sec) 
(<25 poor, >500 great). 
 
 
 
CONCLUSION 
We designed and synthesized new IAS derivatives 8-37 to explore the SARs at the nitrogen of 
the indole-2-carboxamide. The new IASs inhibited the HIV-1 WT NL4-3 strain in MT-4 cells with 
EC50 values at subnanomolar concentrations (except compounds 10 and 26), and showed potent 
inhibition of the mutant K103N, Y181C, Y188L and K103N-Y181C HIV-1 strains. Six racemic 
mixtures, 8, 23-25, 31 and 33, were separated into their pure enantiomers. The (R)-enantiomers of IAS 
derivatives bearing the chiral type B unit (-methylbenzyl) were superior to the (S)-counterparts 
(compare (R)-8 with (S)-8, (R)-3 with (S)-3,21 and (R)-5 with (S)-522). On the contrary, in the case of 
IAS derivatives bearing the chiral type A unit (alanine) the (S)-enantiomer was more potent than the 
corresponding (R)-enantiomer (compare (S)-23 with (R)-23), (S)-31 with (R)-31, (S)-33 and (R)-33). 
The IASs (S,R)-25 and (S,S)-25 bearing the chiral type A+B units ((S)-alanine and (R)- or (S)-(1-
(pyridin-4-yl)ethyl moieties) were superior to the corresponding (R,S)-25 and (R,R)-25 counterparts. 
The docking results showed consistent binding modes in the HIV-1 WT RT as well as in the mutated 
K103N, Y181C and K103N-Y181C RTs. The biological results generally correlated with the length of 
the linker and the configuration of the asymmatric center: the (R) enantiomer of IASs bearing the short 
linker (chiral type B) and the (S) enantiomer with the longer linker (chiral type A unit) were superior to 
the corresponding counterparts. Compound 23 reduced the expression of both iNOS and CD86 (M1 
genes) in BV2 cells while only iNOS was reduced by EFV treatment. On administration to 
hippocampal neuronal cultures in the presence of 100 M glutamate as a neurotoxic stimulus, 
compound 23 protected neurons from the excitotoxic insult, while EFV did not contrast the neurotoxic 
effect of glutamate. The present results highlight the introduction of chiral unit(s), such us of (S)-
alanine and (R)-(-heterocyclylethyl), as a valuable strategy for the design of new series of IAS 
NNRTIs with improved resistance profile against the mutant HIV-1 strains and reduced neurotoxic 
effects. Based on these valuable information, the synthesis of new IAS derivatives is in progress in our 
laboratory and the results will be reported in due course. 
 
 
 
EXPERIMENTAL SECTION 
1. Chemistry. All reagents and solvents were handled according to material safety data sheet of 
the supplier and were used as purchased without further purification. Organic solutions were dried over 
anhydrous sodium sulfate. Evaporation of the solvents was carried out on a B̈chi Rotavapor R-210 
equipped with a B̈chi V-850 vacuum controller and a B̈chi V-700 vacuum pump. Column 
chromatography was performed on columns packed with silica gel from Macherey-Nagel (70−230 
mesh). Silica gel thin layer chromatography (TLC) cards from Macherey-Nagel (silica gel precoated 
aluminum cards with fluorescent indicator visualizable at 254 nm) were used for TLC. Developed 
plates were visualized with a Spectroline ENF 260C/FE UV apparatus. Melting points (mp) were 
determined on a Stuart Scientific SMP1 apparatus and are uncorrected. Infrared spectra (IR) were 
recorded on a PerkinElmer Spectrum 100 FT-IR spectrophotometer equipped with universal attenuated 
total reflectance accessory and IR data acquired and processed by Spectrum 10.03.00.0069 software. 
Band position and absorption ranges are given in cm−1. Proton nuclear magnetic resonance (1H NMR)  
and carbon-13 nuclear magnetic resonance (13C NMR) spectra were recorded with a Varian Mercury 
(300 MHz) or a Bruker Avance (400 MHz) spectrometer in the indicated solvent. Fid files were 
processed by MestreLab Research SL MestreReNova 6.2.1−769 software. Chemical shifts are 
expressed in  units (ppm) from tetramethylsilane. Elemental analyses of biologically evaluated 
compounds were found to be within ±0.4% of the theoretical values and their purity was found to be 
>95% by high pressure liquid chromatography (HPLC). The HPLC system used (Dionex UltiMate 
3000, Thermo Fisher Scientific Inc.) consisted of a SR-3000 solvent rack, a LPG-3400SD quaternary 
analytical pump, a TCC-3000SD column compartment, a DAD-3000 diode array detector, and an 
analytical manual injection valve with a 20 μL loop. Samples were dissolved in acetonitrile (1 mg/mL). 
Thermo Fisher Scientific Inc.), at 25 ± 1 °C with an appropriate solvent gradient (acetonitrile/water), 
flow rate of 1.0 mL/min and signal detector at 206, 230, 254 and 365 nm. Chromatographic data were 
acquired and processed by Chromeleon 6.80 SR15 Build 4656 software (Thermo Fisher Scientific Inc.). 
General Procedure A: Derivatives 8-14 and 17-37. A mixture of acid (0.60 mmol) in anhydrous 
DMF (10 mL/mmol), amine (1.8 mmol), triethylamine (1.8 mmol) and  PyBOP reagent (0.60 mmol) 
was stirred at 25 °C for 12 h. The reaction mixture was diluted with water and extracted with ethyl 
acetate. The organic layer was washed with brine, dried and filtered. Removal of the solvent gave a 
residue that was purified by column chromatography (silica gel, ethyl acetate:n-hexane = 1:2 as eluent). 
General Procedure B: Derivatives 15 and 16. To a solution of acid (0.385 mmol) in anhydrous 
CH2Cl2 (15 mL/mmol), pyridine (0.155 mmol) and oxalyl chloride (0.424 mmol) were added at room 
temperature. The mixture was stirred for 2 h and then the amine (0.424 mmol) was added. The mixture 
was stirred overnight, then diluted with water and extracted with ethyl acetate. The organic layer was 
washed with brine, dried and filtered. Removal of the solvent gave a residue that was purified by 
column chromatography (silica gel, ethyl acetate:n-hexane = 1:2 as eluent). 
General Procedure C: Derivative 17. 1,1′-Carbonyldiimidazole (0.29 mmol) was added to a 
suspension of acid (0.27 mmol) in anhydrous THF (20 mL/mmol). The reaction mixture was stirred at 
25 °C for 2 h, then the amine (0.27 mmol) was added. The reaction mixture was stirred at 25 °C for 2 h 
and diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried 
and filtered. Removal of the solvent gave a residue that was puriﬁed by column chromatography (silica 
gel, ethyl acetate:n-hexane = 3:2 as eluent) and then triturated in n-hexane:acetonitrile = 7:3. 
1.1. 5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(1-(2-fluorophenyl)ethyl)-1H-indole-2-
carboxamide (8). Synthesized following general procedure A, starting from 387 and 1-(2-
fluorophenyl)ethanamine. Yield 78 %, mp 215-217 °C (from ethanol). 1H NMR (400 MHz, DMSO-d6): 
δ 1.53 (s, 3H), 2.27 (s, 6H), 5.38-5.46 (m, 1H), 7.19-7.25 (m, 3H), 7.32-7.34 (m, 2H), 7.51-7.56 (m, 
4H), 7.95 (s, 1H), 9.47 (br s, 1H disappeared on treatment with D2O), 13.03 ppm (br s, 1H, disappeared 
on treatment with D2O). 13C NMR (300 MHz, DMSO-d6):  21.17, 21.78, 44.04, 111.92, 115.37, 
115.69, 115.98, 119.40, 123.98, 125.01, 125.06, 125.23, 125.78, 127.76, 128.18, 128.24, 129.47, 
129.58, 130.49, 130.67, 133.37, 135.16, 137.18, 139.44, 143.01, 158.81 ppm. IR: ν 1651, 3252 cm-1. 
Anal. (C25H22ClFN2O3S (484,97)) C, H, N, Cl, F, S. 
1.2. 5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(1-(furan-2-yl)ethyl)-1H-indole-2-carboxamide 
(9). Synthesized following general procedure A, starting from 387 and 1-(furan-2-yl)ethanamine. Yield 
36%, mp 193-195 °C (from ethanol). 1H NMR (400 MHz, DMSO-d6): δ 1.54 (d, J = 7.0 Hz, 3H), 2.29 
(s, 6H), 5.26-5.30 (m, 1H), 6.43-6.45 (m, 2H), 7.26 (s, 1H), 7.33 (dd, J = 2.2 and 8.8 Hz, 1H), 7.52-
7.54 (m, 1H), 7.58 (s, 2H), 7.63-7.64 (m, 1H), 7.95 (d, J = 1.6 Hz, 1H) ), 9.36 (d, J = 8.2 Hz, 1H, 
disappeared on treatment with D2O), 13.03 ppm (br s, 1H, disappeared on treatment with D2O). 13C 
NMR (300 MHz, DMSO-d6): 
125.23, 125.75, 127.76, 133.35, 135.19, 139.45, 142.74, 142.94, 155.38, 158.82 ppm. IR: ν 1650, 3235 
cm-1. Anal. (C23H21ClN2O4S (456.94)) C, H, N, Cl, S.  
1.3. 5-Chloro-N-((4-chlorophenyl)(cyclopropyl)methyl)-3-((3,5-dimethylphenyl)sulfonyl)-1H-indole-2-
carboxamide (10). Synthesized following general procedure A, starting from 387 and (4-
chlorophenyl)(cyclopropyl)methanamine. Yield 54%, mp 243-245 °C (from ethanol). 1H NMR (400 
MHz, DMSO-d6): δ 0.51-0.61 (m, 4H), 1.23-1.31 (m, 1H), 2.27 (s, 6H), 4.48-4.52 (m, 1H), 7.25 (s, 1H), 
7.33 (dd, J = 2.1 and 8.9 Hz, 1H), 7.41-7.43 (m, 2H), 7.51-7.54 (m, 3H), 7.59 (s, 2H), 7.94 (d, J = 2.0 
Hz, 1H), 9.60 (d, J = 7.0 Hz, 1H, disappeared on treatment with D2O), 13.00 ppm (br s, 1H, 
disappeared on treatment with D2O). 13C NMR (300 MHz, DMSO-d6): 
57.38, 111.82, 115.41, 119.41, 123.97, 125.22, 125.86, 127.77, 128.68, 129.12, 132.11, 133.42, 135.18, 
137.15, 139.46, 141.74, 143.00, 158.91 ppm. IR: ν 1647, 3180, 3288 cm-1. Anal. (C27H24Cl2N2O3S 
(527.46)) C, H, N, Cl, S. 
1.4. 5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(2-fluoro-6-methoxybenzyl)-1H-indole-2-
carboxamide (11). Synthesized following general procedure A, starting from 387 and (2-fluoro-6-
methoxyphenyl)methanamine. Yield 52%, mp 295-297 °C (from ethanol). 1H NMR (400 MHz, 
DMSO-d6): δ 2.23 (s, 6H), 3.85 (s, 3H), 4.61 (d, J = 4.9 Hz, 2H), 6.86 (t, J = 8.5 Hz, 1H), 6.94 (d, J = 
7.9 Hz, 1H), 7.23 (s, 1H), 7.30-7.40 (m, 2H), 7.44 (s, 2H), 7.51 (d, J = 8.2 Hz, 1H), 7.99 (d, J = 2.0 Hz, 
1H), 9.23 (br s, 1H, disappeared on treatment with D2O), 13.06 ppm (br s, 1H, disappeared on 
treatment with D2O). 13C NMR (300 MHz, DMSO-d6): 
56.09, 107.21, 107.70, 108.04, 112.52, 115.18, 117.96, 119.97, 123.54, 125.53, 126.70, 126.94, 128.31, 
130.25, 130.40, 133.32, 135.19, 139.78, 162.14 ppm. IR: ν 1645, 3195 cm-1. Anal. (C25H22ClFN2O4S 
(500.97)) C, H, N, Cl, F, S. 
1.5. 5-Chloro-N-(1-(3,5-difluorophenyl)ethyl)-3-((3,5-dimethylphenyl)sulfonyl)-1H-indole-2-
carboxamide (12). Synthesized following general procedure A, starting from 387 and 1-(3,5-
difluorophenyl)ethanamine. Yield 73%, mp 238-240 °C (from ethanol). 1H NMR (400 MHz, DMSO-
d6): δ 1.50 (d, J = 7.0 Hz, 3H), 2.28 (s, 6H), 5.19-5.22 (m, 1H), 7.10-7.14 (m, 1H), 7.21-7.24 (m, 3H), 
7.34 (d, J = 2.1 and J = 8.8 Hz, 1H), 7.53-7.55 (m, 1H), 7.60 (s, 2H), 7.92 (d, J = 2.0 Hz, 1H), 9.42 (d, 
J = 7.3 Hz, 1H disappeared on treatment with D2O), 13.04 ppm (br s, 1H, disappeared on treatment 
with D2O). 13C NMR (300 MHz, DMSO-d6,): 
110.08, 111.95, 115.29, 119.29, 124.16, 125.08, 127.66, 133.41, 135.05, 137.83, 139.34, 143.03, 
159.42, 161.17, 164.42 ppm. IR: ν 1648, 2923, 3215 cm-1. Anal. (C25H21ClF2N2O3S (502.96)) C, H, N, 
Cl, F, S. 
1.6. 5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(2-fluoro-1-phenylethyl)-1H-indole-2-
carboxamide (13). Synthesized following general procedure A, starting from 387 and 2-fluoro-1-
phenylethanamine. Yield 52%, mp 216-218 °C (from ethanol). 1H NMR (400 MHz, DMSO-d6): δ 2.26 
(s, 6H), 4.66-4.68 (m, 1H), 4.78-4.80 (m, 1H), 5.42-5.52 (m, 1H), 7.25 (s, 1H), 7.32-7.42 (m, 4H), 
7.51-7.55 (m, 3H), 7.59 (s, 2H), 7.97 (d, J = 1.9 Hz, 1H), 9.74 (d, J = 7.9 Hz, 1H, disappeared on 
treatment with D2O), 13.08 ppm (br d, J = 4.6 Hz, 1H, disappeared on treatment with D2O). 13C NMR 
(300 MHz, DMSO-d6,): 
125.83, 127.73, 127.85, 128.26, 128.96, 133.42, 135.22, 136.57, 137.80, 137.87, 139.50, 142.88, 
159.36 ppm. IR: ν 1650, 3235 cm-1. Anal. (C25H22ClFN2O3S (484.97)) C, H, N, Cl, F, S. 
1.7. 5-Chloro-N-(2,3-difluorobenzyl)-3-((3,5-dimethylphenyl)sulfonyl)-1H-indole-2-carboxamide (14). 
Synthesized following general procedure A, starting from 387 and (2,3-difluorophenyl)methanamine. 
Yield 47%, mp 255-257 °C (from ethanol). 1H NMR (400 MHz, DMSO-d6): δ 2.27 (s, 6H), 4.65 (d, J = 
5.7 Hz, 2H), 7.20-7.24 (m, 2H), 7.32-7.41 (m, 3H), 7.52-7.54 (m, 1H), 7.59 (s, 2H), 7.93 (d, J = 1.9 Hz, 
1H), 9.50 (t, J = 5.6 Hz, 1H, disappeared on treatment with D2O) 13.07 ppm (br s, 1H, disappeared on 
treatment with D2O). 13C NMR (300 MHz, DMSO-d6): 
116.93, 119.34, 124.10, 125.20, 125.61, 127.72, 127.99, 128.14, 133.40, 135.10, 137.19, 139.37, 
142.93, 160.05 ppm.  IR: ν 1649, 3214 cm-1. Anal. (C24H19ClF2N2O3S (488.93)) C, H, Cl, F, N, S. 
1.8. 5-Chloro-N-(4-cyanopyridin-2-yl)-3-((3,5-dimethylphenyl)sulfonyl)-1H-indole-2-carboxamide (15). 
Synthesized following general procedure B, starting from 387 and 2-aminoisonicotinonitrile. Yield 7%, 
mp 233-235 °C (from ethanol). 1H NMR (400 MHz DMSO-d6): δ 2,29 (s, 6H), 7.26 (s, 1H), 7.37 (dd, J 
= 2.0 and 8.5 Hz, 1H), 7.58-7.60 (m, 1H), 7.65 (s, 2H), 7.71 (dd, J = 1.4 e 5.1 Hz, 1H), 7.95 (d, J = 2.0 
Hz, 1H), 8.49 (s, 1H), 8.69 (d, J = 5.1 Hz, 1H), 11.78 (br, s, 1H disappeared on treatment with D2O), 
13.28 ppm (br s, 1H, disappeared on treatment with D2O). 13C NMR (300 MHz, DMSO-d6,): 
115.94, 116.20, 117.21, 117.89, 119.40, 121.80, 122.36, 124.29, 125.08, 125.11, 126.13, 127.66, 
135.07, 139.36, 150.60, 152.16, 159.70 ppm. IR: ν 1664, 2923, 3324 cm-1. Anal. (C23H17ClN4O3S 
(464.92)) C, H, N, Cl, S. 
1.9. 5-Chloro-N-(2-cyanopyridin-4-yl)-3-((3,5-dimethylphenyl)sulfonyl)-1H-indole-2-carboxamide (16). 
Synthesized following general procedure B, starting from 387 and 4-aminopicolinonitrile. Yield 11%, 
mp 223-225 °C (from ethanol). 1H NMR (400 MHz DMSO-d6): δ 2.31-2.32 (m, 6H), 7.26-7.28 (m, 
1H), 7.37 (dd, J = 2.7 and  8.9 Hz, 1H), 7.43 (dd, J = 2.1 e 8.8 Hz, 1H), 7.59-7.61 (m, 2H), 7.65 (s, 1H), 
7.93-7.95 (m, 1H), 8.21 (d, J = 1,6 Hz, 1H), 8.72-8.73 (m, 1H), 11.68 (br, s, 1H disappeared on 
treatment with D2O), 13.30 ppm (br s, 1H, disappeared on treatment with D2O). 13C NMR (300 MHz, 
DMSO-d6): 
128.25, 131.14, 133.72, 134.14, 134.95, 135.11, 137.02, 139.08, 139.37, 142.77, 143.14, 146.46, 
152.98, 159.47, 160.27 ppm. IR: ν 1693, 2923, 3275 cm-1. Anal. (C23H17ClN4O3S (464.92)) C, H, Cl, N, 
S. 
1.10. N-(3-Aminobenzyl)-5-chloro-3-((3,5-dimethylphenyl)sulfonyl)-1H-indole-2-carboxamide (17). 
Synthesized following general procedure C, starting from 387 and 3-(aminomethyl)aniline.  Yield 71%, 
mp 239-241 °C (from ethanol). 1H NMR (400 MHz, DMSO-d6): δ 2.27 (s, 6H), 4.42 (d, J = 5.8 Hz, 
2H), 5.04 (s, 2H, disappeared on treatment with D2O), 6.47-6.49 (m, 1H), 6.57-6.59 (m, 2H), 7.0 (t, J = 
7.7 Hz, 1H), 7.24 (s, 1H), 7.33 (dd, J = 1.7 and 8.6 Hz, 1H), 7.52-7.54 (m, 1H), 7.58 (s, 2H), 7.95 (d, J 
= 2.0 Hz, 1H), 9.35 (t, J = 7.0 Hz, 1H, disappeared on treatment with D2O), 13.04 ppm (br s, 1H, 
disappeared on treatment with D2O). 13C NMR (300 MHz, DMSO-d6): 
113.63, 115.40, 115.53, 119.45, 124.06, 125.21, 125.87, 127.74, 129.40, 133.32, 135.18, 137.11, 
139.01, 139.47, 142.92, 149.18, 159.41 ppm. IR: ν 1655, 2936, 3297 cm-1. Anal. (C24H22ClN3O3S 
(467.97)) C, H, N, Cl, S. 
1.11. N-((2-Amino-1H-benzo[d]imidazol-5-yl)methyl)-5-chloro-3-((3,5-dimethylphenyl)sulfonyl)-1H-
indole-2-carboxamide (18). Synthesized following general procedure A, starting from 387 and 5-
(aminomethyl)-1H-benzo[d]imidazol-2-amine. Yield 51%, mp 245-248 °C (from ethanol). 1H NMR 
(400 MHz, DMSO-d6/D2O): δ 2.20 (s, 6H), 4.56 (s, 2H), 6.96-6.98 (m, 1H), 7.09 (d, J = 7.8 Hz, 1H), 
7.21-7.22 (m, 2H), 7.34 (dd, J = 2.1 and 8.6 Hz, 1H), 7.50-7.54 (m, 3H), 7.93 (d, J = 1.6 Hz, 1H). IR: ν 
1648, 3276, 3364 cm-1. 13C NMR (300 MHz, DMSO-d6,): 
115.38, 119.45, 119.93, 123.99, 125.18, 125.90, 127.74, 129.51, 133.32, 135.14, 137.20, 139.44, 
142.94, 155.70, 159.23 ppm. Anal. (C25H22ClN5O3S (507.99)) C, H, N, Cl, S. 
1.12. N-((1H-Indazol-3-yl)methyl)-5-chloro-3-((3,5-dimethylphenyl)sulfonyl)-1H-indole-2-carboxa-
mide (19). Synthesized following general procedure A, starting from 387 and (1H-indazol-3-
yl)methanamine. Yield 35%, mp 248-250 °C (from ethanol). 1H NMR (400 MHz, DMSO-d6): δ 2.20 (s, 
6H), 4.93 (d, J = 5.6 Hz, 2H), 7.10 (t, J = 7.1 Hz, 1H), 7.21 (s, 1H), 7.30-7.37 (m, 2H), 7.50-7.55 (m, 
4H), 7.90-7.93 (m, 1H), 7.97 (d, J = 2.0 Hz, 1H), 9.51 (br s, 1H, disappeared on treatment with D2O), 
12.96 (s, 1H, disappeared on treatment with D2O), 13.06 (br s, 1H, disappeared on treatment with D2O). 
13C NMR (400 MHz, DMSO-d6): 
120.81, 121.51, 121.56, 124.05, 126.68, 134.72, 135.10, 141.54, 154.43, 163.58 ppm.  IR: ν 1646, 2924, 
3195 cm-1. Anal. (C25H21ClN4O3S (492.98)). C, H, N, Cl, S. 
1.13. 5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(2-oxo-2-((1-phenylethyl)amino)ethyl)-1H-indole-2-
carboxamide (20). Synthesized following general procedure A, starting from 39 and 1-
phenylethanamine. Yield 27%, mp 227-230 °C with decomposition (from ethanol). 1H NMR (400 MHz, 
DMSO-d6): δ 1.39 (d, J = 7.0 Hz, 3H), 2.27 (s, 6H), 4.07-4.10 (m, 2H), 4.97-5.02 (m, 1H), 7.21-7.34 
(m, 7H), 7.54 (d, J = 8.6 Hz, 1H), 7.71 (s, 2H), 7.98 (s, 1H), 8.39 (d, J = 8.6 Hz, 1H, disappeared on 
treatment with D2O), 9.41 (s, 1H, disappeared on treatment with D2O), 13.08 ppm (br s, 1H, 
disappeared on treatment with D2O). 13C NMR (400 MHz, DMSO-d6,):  21.12, 22.90, 43.35, 48.59, 
112.02, 115.69, 119.46, 124.21, 125.29, 125.94, 126.42, 127.16, 127.78, 128.71, 135.29, 136.59, 
139.56, 142.77, 144.82, 159.97, 167.45 ppm. IR: ν 1535, 1648, 2921, 3258 cm-1. Anal. 
(C27H26ClN3O4S (524.03)): C, H, N, Cl, S. 
1.14. 5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(1-oxo-1-((1-phenylethyl)amino)propan-2-yl)-1H-
indole-2-carboxamide (21). Synthesized following general procedure A, starting from 40 and 1-
phenylethanamine. Yield 38%, mp 209-212 °C (from ethanol). 1H NMR (400 MHz, DMSO-d6): δ 
1.36-1.43 (m, 6H), 2.22-2.30 (m, 6H), 4.61-4.66 (m, 1H), 4.95-5.01 (m, 1H), 7.21-7.37 (m, 7H), 7.52-
7.57 (m, 1H), 7.69 (s, 2H), 8.00-8.02 (m, 1H), 8.49 (br s, 1H, disappeared on treatment with D2O), 9.40 
(br s, 1H, disappeared on treatment with D2O), 13.06 ppm (br s, 1H, disappeared on treatment with 
D2O). 13C NMR (400 MHz, DMSO-d6): 
49.59, 49.70, 119.50, 124.08, 124.12, 126.23, 126.41, 127.11, 128.71, 128.74, 135.27, 139.53, 142.91, 
144.70, 144.99, 170.85, 170.98 ppm. IR: ν 1524, 1642, 3234 cm-1. Anal. (C28H28ClN3O4S (538.06)): C, 
H, N, Cl, S. 
1.15. 5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(2-oxo-2-((pyridin-4-ylmethyl)amino)ethyl)-1H-
indole-2-carboxamide (22). Synthesized following general procedure A, starting from 39 and pyridin-
4-ylmethanamine. Yield 45%, mp 276-279 °C (from ethanol). 1H NMR (400 MHz, DMSO-d6): δ 2.27 
(s, 6H), 4.13 (d, J = 5.7, 2H), 4.39 (d, J = 6.0, 2H), 7.24 (s, 1H), 7.30-7.33 (m, 3H), 7.55 (d, J = 9.0 Hz, 
1H), 7.70 (s, 2H), 7.97 (s, 1H), 8.47 (d, J = 4.9 Hz, 2H,), 8.64 (br s, 1H, disappeared on treatment with 
D2O), 9.43 (s, 1H, disappeared on treatment with D2O), 13.14 ppm (br s, 1H, disappeared on treatment 
with D2O). 13C NMR (400 MHz, DMSO-d6):  21.16, 21.34, 41.59, 43.41, 111.83, 115.86, 119.34, 
122.57, 124.27, 124.90, 126.14, 127.52, 135.05, 139.36, 143.09, 148.79, 149.85, 160.49, 169.01 ppm. 
IR: ν 1558, 1647, 2922, 3310 cm-1. Anal. (C25H23ClN4O4S (510.99)): C, H, N, Cl, S. 
1.16. 5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(1-oxo-1-((pyridin-4-ylmethyl)amino)propan-2-yl)-
1H-indole-2-carboxamide (23). Synthesized following general procedure A, starting from 40 and 
pyridin-4-ylmethanamine. Yield 49%, mp 112-115 °C (from ethanol). 1H NMR (400 MHz, DMSO-d6): 
δ 1.45 (d, J = 6.6 Hz, 3H), 2.28 (s, 6H), 4.38 (s, 2H), 4.61-4.65 (m, 1H), 7.26-7.29 (m, 3H), 7.35 (d, J = 
8.1 Hz, 1H), 7.56 (d, J = 8.6 Hz, 1H), 7.68 (s, 2H), 8.00 (s, 1H), 8.48 (d, J = 4.4 Hz, 2H), 8.69 (t, J = 
4.7 Hz, 1H, disappeared on treatment with D2O) 9.43 (br s, 1H, disappeared on treatment with D2O), 
13.04 ppm (br s, 1H, disappeared on treatment with D2O). 13C NMR (300 MHz, DMSO-d6,):  18.66, 
21.11, 41.60, 49.83, 112.25, 115.56, 119.55, 121.84, 122.38, 124.09, 125.46, 125.92, 127.90, 133.33, 
135.33, 136.10, 139.57, 142.71, 148.69, 149.93, 159.03, 172.22 ppm. IR: ν 1566, 1648, 2936, 3220 cm-
1
. Anal. (C26H25ClN4O4S (525.02)): C, H, N, Cl, S. 
1.17. 5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(2-oxo-2-((1-(pyridin-4-yl)ethyl)amino)ethyl)-1H-
indole-2-carboxamide (24). Synthesized following general procedure A, starting from 39 and 1-
(pyridin-4-yl)ethanamine. Yield 40%, mp 238-240 °C dec. (from ethanol). 1H NMR (400 MHz, 
DMSO-d6): δ 1.39 (d, J = 6.5 Hz, 3H), 2.26 (s, 6H), 4.13 (d, J = 5.6 Hz, 2H), 4.96-4.99 (m, 1H), 7.25 (s, 
1H), 7.35 (d, J = 4.8 Hz, 3H), 7.54 (d, J = 8.9 Hz, 1H), 7.71 (s, 2H), 7.97 (s, 1H), 8.48-8.49 (m, 2H), 
8.52 (br s, 1H, disappeared on treatment with D2O), 9.47 (t, J = 3.8 Hz, 1H, disappeared on treatment 
with D2O), 13.10 ppm (br s, 1H, disappeared on treatment with D2O). 13C NMR (300 MHz, DMSO-
d6):  21.10, 22.11, 43.35, 47.94, 170.49, 119.50, 121.64, 124.19, 128.08, 135.44, 139.60, 142.71, 
150.02, 153.60, 159.92, 162.21, 167.89, 171.85, 172.48, 174.76, 177.84, 181.21 ppm. IR: ν 1561, 1648, 
2926, 3258 cm-1. Anal. (C26H25ClN4O4S (525.02)) C, H, N, Cl, S. 
1.18. 5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(1-oxo-1-((1-(pyridin-4-yl)ethyl)amino)propan-2-
yl)-1H-indole-2-carboxamide (25). Synthesized following general procedure A, starting from 40 and 1-
(pyridin-4-yl)ethanamine. Yield 12%, mp 130-133 °C (from ethanol). 1H NMR (400 MHz, DMSO-d6): 
δ 1.38-1.43 (m, 6H), 2.23-2.28 (m, 6H), 4.60-4.66 (m, 1H), 4.91-4.98 (m, 1H), 7.23-7.26 (m, 1H), 7.33-
7.35 (m, 3H), 7.54-7.56 (m, 1H), 7.67 (s, 2H), 7.99 (s, 1H), 8.45-8.50 (m, 2H), 8.55-8.62 (m, 1H, 
disappeared on treatment with D2O), 9.39 (s, 1H, disappeared on treatment with D2O), 13.08 ppm (br s, 
1H, disappeared on treatment with D2O). 13C NMR (400 MHz, DMSO-d6,):  18.74, 21.08, 21.14, 
22.11, 47.96, 49.68, 108.92, 115.70, 119.48, 121.51, 121.61, 124.11, 127.82, 135.32, 139.56, 149.99, 
150.05, 152.29, 153.02, 153.71, 154.51, 155.42, 159.02, 171.22 ppm. IR: ν 1551, 1650, 2924, 3266 cm-
1
. Anal. (C27H27ClN4O4S (539.05)) C, H, N, Cl, S. 
1.19. 5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(2-oxo-2-((2-(thiophen-2-yl)ethyl)amino)ethyl)-1H-
indole-2-carboxamide (26). Synthesized following general procedure A, starting from 39 and 2-
(thiophen-2-yl)ethanamine. Yield 42%, mp 160-164 °C (from ethanol). 1H NMR (400 MHz, DMSO-
d6): δ 2.31 (s, 6H), 2.95-2.99 (m, 2H), 3.36-3.41 (m, 2H), 4.04 (d, J = 4.5 Hz, 2H), 6.90-6.95 (m, 2H), 
7.27 (s, 1H), 7.31-7.37 (m, 2H), 7.55 (dd, J = 2.4 and 9.2 Hz, 1H), 7.73 (s, 2H), 8.00 (s, 1H), 8.19 (br s, 
1H, disappeared on treatment with D2O), 9.39 (br s, 1H, disappeared on treatment with D2O), 13.07 
ppm (br s, 1H, disappeared on treatment with D2O). 13C NMR (DMSO-d6, 300 MHz):  21.18, 29.67, 
41.53, 43.31, 109.98, 112.29, 115.56, 119.57, 124.20, 124.48, 125.46, 125.68, 127.44, 127.89, 133.37, 
135.35, 139.58, 141.69, 142.71, 159.59, 164.08, 168.35 ppm. IR: ν 1545, 1638, 2922, 3213 cm-1. Anal. 
(C25H24ClN3O4S2 (530.06)) C, H, N, Cl, S. 
1.20. 5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(1-oxo-1-((2-(thiophen-2-yl)ethyl)amino) propan-2-
yl)-1H-indole-2-carboxamide (27). Synthesized following general procedure A, starting from 40 and 2-
(thiophen-2-yl)ethanamine. Yield 41%, mp 227-230 °C (from ethanol). 1H NMR (400 MHz, DMSO-
d6): δ 1.36 (d, J = 7.1 Hz, 3H), 2.30 (s, 6H), 2.95-2.99 (m, 2H), 3.36-3.45 (m, 2H), 4.51-4.58 (m, 1H), 
6.89-6.91 (m, 1H), 6.93-6.95 (m, 1H), 7.27 (s, 1H), 7.32-7.37 (m, 2H), 7.56 (d, J = 8.6 Hz, 1H), 7.70 (s, 
2H), 8.02 (s, 1H), 8.25 (t, J = 6.2 Hz, 1H, disappeared on treatment with D2O), 9.37 (br s, 1H, 
disappeared on treatment with D2O), 13.04 ppm (br s, 1H, disappeared on treatment with D2O). 13C 
NMR (300 MHz, DMSO-d6):  18.86, 21.13, 29.60, 40.93, 49.70, 112.29, 115.52, 119.63, 124.10, 
124.48, 125.51, 125.73, 125.97, 127.39, 127.94, 133.23, 135.38, 135.90, 139.60, 141.71, 142.73, 
158.66, 171.74 ppm. IR: ν 1566, 1648, 2936, 3217 cm-1. Anal. (C26H26ClN3O4S2 (544.09)) C, H, N, Cl, 
S. 
1.21. 5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(2-((2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl) 
amino)-2-oxoethyl)-1H-indole-2-carboxamide (28). Synthesized following general procedure A, 
starting from 39 and 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethanamine. Yield 98%, mp 212-215 °C 
(from ethanol). 1H NMR (300 MHz, DMSO-d6): δ 2.30 (s, 6H), 2.42 (s, 3H), 3.48-3.55 (m, 2H), 3.97 (d, 
J = 5.7 Hz, 2H), 4.33-4.36 (m, 2H), 7.26 (s, 1H), 7.32-7.36 (m, 1H), 7.54 (d, J = 9.0 Hz, 1H), 7.70 (s, 
2H), 7.99 (d, J = 9.8 Hz, 2H), 8.27 (t, J = 6.4 Hz, 1H, disappeared on treatment with D2O), 9.37 (br s, 
1H disappeared on treatment with D2O), 13.84 ppm (br s, 1H, disappeared on treatment with D2O). 13C 
NMR (400 MHz, DMSO-d6):  14.30, 21.15, 38.63, 43.07, 45.81, 115.71, 119.56, 121.01, 124.21, 
125.40, 126.08, 127.82, 133.70, 135.33, 138.54, 138.92, 139.59, 140.54, 142.78, 151.93, 169.08 ppm. 
IR: ν 1642, 1678, 2922, 3255 cm-1. Anal. (C25H25ClN6O6S (573.02)) C, H, N, Cl, S. 
1.22. 5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(1-((2-(2-methyl-5-nitro-1H-imidazol-1 
yl)ethyl)amino)-1-oxopropan-2-yl)-1H-indole-2-carboxamide (29). Synthesized following general 
procedure A, starting from 40 and 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethanamine. Yield 74%, mp 
138-140 °C with decomposition (from ethanol). 1H NMR (300 MHz, DMSO-d6): δ 1.25 (d, J = 7.0 Hz, 
3H), 2.29 (s, 6H), 2.42 (s, 3H), 3.42-3.48 (m, 2H), 4.29-4.36 (m, 2H), 4.38-4.47 (m, 1H), 7.26 (s, 1H), 
7.31-7.35 (m, 1H), 7.54 (d, J = 8.8 Hz, 1H), 7.66 (s, 2H), 7.98-8.00 (m, 2H), 8.32 (t, J = 6.1 Hz, 1H, 
disappeared on treatment with D2O), 9.30 (br s, 1H, disappeared on treatment with D2O), 13.00 ppm 
(br s, 1H, disappeared on treatment with D2O). 13C NMR (300 MHz, DMSO-d6):  14.39, 18.42, 21.13, 
38.38, 45.75, 49.51, 112.26, 115.54, 119.58, 124.06, 125.49, 125.95, 127.92, 133.28, 133.62, 135.35, 
135.87, 138.99, 139.60, 142.70, 151.90, 158.73, 172.34 ppm. IR: ν 1561, 1641, 2967, 3234 cm-1. Anal. 
(C26H27ClN6O6S (587.05)) C, H, N, Cl, S. 
1.23. 5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(2-oxo-2-((pyrimidin-4-ylmethyl)amino)ethyl)-1H-
indole-2-carboxamide (30). Synthesized following general procedure A, from 39 and pyrimidin-4-
ylmethanamine. Yield 67%, mp 233-235 °C (from ethanol). 1H NMR (400 MHz, DMSO-d6): δ 2.25 (s, 
6H), 4.16 (d, J = 7.4 Hz, 2H), 4.43 (d, J = 7.8 Hz, 2H), 7.24 (s, 1H), 7.33 (dd, J = 2.1 and 11.5 Hz, 1H), 
7.47 (d, J = 6.5 Hz, 1H), 7.54 (d, J = 11.6, 1H), 7.69 (s, 2H), 7.98 (d, J = 2.6 Hz, 1H), 8.69-8.72 (m, 
2H), 9.09 (br s, 1H, disappeared on treatment with D2O), 9.45 (t, J = 6.5 Hz, 1H, disappeared on 
treatment with D2O), 13.05 ppm (br s, 1H, disappeared on treatment with D2O). 13C NMR (300 MHz, 
DMSO-d6,):  21.08, 43.41, 44.11, 112.41, 115.53, 118.92, 119.58, 124.16, 125.48, 125.89, 127.92, 
133.32, 135.30, 135.96, 139.55, 142.70, 157.71, 158.70, 159.76, 167.66, 169.05 ppm. IR: ν 1555, 1649, 
2928, 3265 cm-1. Anal. (C24H22ClN5O4S (511.98)) C, H, N, Cl, S. 
1.24. 5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(1-oxo-1-((pyrimidin-4-ylmethyl)amino) propan-2-
yl)-1H-indole-2-carboxamide (31). Synthesized following general procedure A, starting from 40 and 
pyrimidin-4-ylmethanamine. Yield 80%, mp 108-110 °C (from ethanol). 1H NMR (400 MHz, DMSO-
d6): δ 1.46 (d, J = 7.1 Hz, 3H), 2.26 (s, 6H), 4.42-4.44 (m, 2H), 4.64-4.67 (m, 1H), 7.25 (s, 1H), 7.36 
(dd, J = 2.0 and 8.8 Hz, 1H), 7.46 (d, J = 5.0 Hz, 1H), 7.56 (d, J = 8.8 Hz, 1H), 7.68 (s, 2H), 8.0 (d, J = 
2.0 Hz, 1H), 8.71 (d, J = 5.2 Hz, 1H), 8.81 (t, J = 6.0 Hz, 1H), 9.09 (d, J = 1.1 Hz, 1H, disappeared on 
treatment with D2O), 9.46 (d, J = 6.7 Hz, 1H, disappeared on treatment with D2O), 13.07 ppm (br s, 1H, 
disappeared on treatment with D2O). 13C NMR (300 MHz, DMSO-d6,):  18.55, 21.08, 44.10, 49.84, 
112.29, 115.54, 118.76, 119.55, 124.06, 125.47, 125.92, 127.91, 133.33, 135.32, 136.06, 139.56, 
142.71, 157.75, 158.47, 159.07, 167.71, 172.48 ppm.  
IR: ν 1554, 1649, 2967, 3268 cm-1. Anal. (C25H24ClN5O4S (526.01)) C, H, N, Cl, S. 
1.25. 5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(2-((furan-2-ylmethyl)amino)-2-oxoethyl)-1H-
indole-2-carboxamide (32). Synthesized following general procedure A, starting from 39 and furan-2-
ylmethanamine. Yield 56%, mp 200-202 °C (from ethanol). 1H NMR (300 MHz, DMSO-d6): δ 2.27 (s, 
6H), 4.05 (d, J = 5.4 Hz, 2H), 4.32 (d, J = 4.32 Hz, 2H), 6.25-6.26 (m, 1H), 6.35-6.36 (m, 1H), 7.23 (s, 
1H), 7.30-7.33 (m, 1H), 7.51-7.54 (m, 2H), 7.69 (s, 2H), 7.97 (s, 1H), 8.48 (t, J = 5.3 Hz, 1H, 
disappeared on treatment with D2O), 9.34 (br s, 1H, disappeared on treatment with D2O), 13.02 ppm 
(br s, 1H, disappeared on treatment with D2O). 13C NMR (300 MHz, DMSO-d6,):  21.10, 36.00, 43.22, 
107.47, 110.90, 112.41, 115.52, 119.60, 124.20, 125.49, 125.88, 127.91, 133.26, 135.33, 135.90, 
139.57, 142.64, 152.39, 159.55, 168.26 ppm. IR: ν 1544, 1643, 2922, 3217 cm-1. Anal. 
(C24H22ClN3O5S (499.97)) C, H, N, Cl, S. 
1.26. 5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(1-((furan-2-ylmethyl)amino)-1-oxopropan-2-yl)-
1H-indole-2-carboxamide (33). Synthesized following general procedure A, starting from 40 and 
furan-2-ylmethanamine. Yield 87%, mp 215-217 °C (from ethanol). 1H NMR (300 MHz, DMSO-d6): δ 
1.38 (d, J = 5.3 Hz, 3H), 2.29 (s, 6H), 4.33-4.35 (m, 2H), 4.55-4.62 (m, 1H), 6.27 (d, J = 3.0 Hz, 1H), 
6.38-6.39 (m, 1H), 7.26 (s, 1H), 7.32-7.35 (m, 1H), 7.54-7.57 (m, 2H), 7.68 (s, 2H), 8.01 (d, J = 1.9 Hz, 
1H), 8.56 (t, J = 5.8 Hz, 1H, disappeared on treatment with D2O), 9.36 (br s, 1H, disappeared on 
treatment with D2O), 13.04 ppm (br s, 1H, disappeared on treatment with D2O). 13C NMR (DMSO-d6, 
300 MHz):  18.84, 21.12, 36.12, 49.63, 107.28, 110.91, 115.51, 119.61, 124.09, 125.50, 125.96, 
127.93, 133.25, 135.35, 135.90, 139.59, 142.61, 142.72, 152.42, 158.71, 171.71 ppm. IR: ν 1541, 1648, 
3276 cm-1. Anal. (C25H24ClN3O5S (513.99)) C, H, N, Cl, S. 
1.27. 5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(2-((2-fluorobenzyl)amino)-2-oxoethyl)-1H-indole-
2-carboxamide (34). Synthesized following general procedure A, starting from 39 and (2-
fluorophenyl)methanamine. Yield 52%, mp 230-232 °C (from ethanol). 1H NMR (300 MHz, DMSO-
d6): δ 2.27 (s, 6H), 4.10 (d, J = 5.3 Hz, 2H), 4.39 ( d, J = 5.5 Hz, 2H), 7.11-7.18 (m, 2H), 7.24-7.41 (m, 
4H), 7.52-7.55 (m, 1H), 7.69 (s, 2H), 7.98 (d, J = 1.6 Hz, 1H), 8.53 (t, J = 5.9 Hz, 1H, disappeared on 
treatment with D2O), 9.40 (br s, 1H, disappeared on treatment with D2O), 12.91 (br s, 1H, disappeared 
on treatment with D2O). 13C NMR (300 MHz, DMSO-d6):  21.07, 36.47, 43.30, 112.40, 115.34, 
115.58, 119.60, 124.18, 124.72, 125.46, 125.93, 126.24, 127.91, 129.47, 130.07, 133.35, 135.30, 
136.01, 139.56, 142.73, 159.67, 168.52 ppm. IR: ν 1542, 1632, 2920, 3216 cm-1. Anal. 
(C26H23ClFN3O4S (527,99)) C, H, N, Cl, F, S. 
1.28. 5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(1-((2-fluorobenzyl)amino)-1-oxopropan-2-yl)-1H-
indole-2-carboxamide (35). Synthesized following general procedure A, starting from 40 and (2-
fluorophenyl)methanamine. Yield 52%, mp 210-212 °C (from ethanol). 1H NMR (400 MHz, DMSO-
d6): δ 1.41 (d, J = 7.0 Hz, 3H), 2.28 (s, 6H), 4.39 (d, J = 5.3 Hz, 2H), 4.60-4.63 (m, 1H), 7.13-719 (m, 
2H), 7.25 (s, 1H), 7.27-7.39 (m, 3H), 7.54-7.56 (m, 1H), 7.68 (s, 2H), 8.01 (d, J = 1.8 Hz, 1H), 8.60 (t, 
J = 6.6 Hz, 1H, disappeared on treatment with D2O), 9.37 (br s, 1H, disappeared on treatment with 
D2O), 13.02 (br s, 1H, disappeared on treatment with D2O).  13C NMR (300 MHz, DMSO-d6):  18.79, 
21.09, 36.46, 49.72, 112.32, 115.35, 115.53, 119.61, 124.09, 124.77, 125.48, 125.96, 126.26, 127.92, 
129.32, 129.43, 129.80, 133.29, 135.33, 135.96, 139.57, 142.72, 158.83, 171.95 ppm. IR: ν 1568, 1647, 
3275 cm-1. Anal. (C27H25ClFN3O4S (542,02)) C, H, N, Cl, F, S. 
1.29. 5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(2-((1-(2-fluorophenyl)ethyl)amino)-2-oxoethyl)-
1H-indole-2-carboxamide (36). Synthesized following general procedure A, starting from 39 and 1-(2-
fluorophenyl)ethanamine. Yield 29%, mp 230-232 °C (from ethanol). 1H NMR (400 MHz, DMSO-d6): 
δ 1.38 (d, J = 7.0 Hz, 3H), 2.26 (s, 6H), 4.10-4.11 (s, 2H), 5.21-5.24 (m, 1H), 7.12-7.16 (m, 2H), 7.25-
7.28 (m, 2H), 7.34 (d, J = 9.2 Hz, 1H), 7.44 (t, J = 8.4 Hz, 1H), 7.54 (d, J = 8.6 Hz, 1H), 7.71 (s, 2H), 
7.98 (s, 1H), 8.50 (d, J = 7.2 Hz, 1H, disappeared on treatment with D2O), 9.42 (br s, 1H, disappeared 
on treatment with D2O), 13.07 ppm (br s, 1H, disappeared on treatment with D2O). 13C NMR (400 
MHz, DMSO-d6,):  21.08, 21.90, 43.00, 43.25, 115.57, 115.71, 115.78, 119.47, 124.20, 124.88, 
124.91, 125.29, 127.70, 127.75, 129.11, 129.19, 131.63, 131.77, 135.29, 139.56, 142.76, 158.63, 
161.05, 167.58 ppm.  IR: ν 1538, 1637, 2925, 3219 cm-1. Anal. (C27H25ClFN3O4S (542.02)) C, H, N, Cl, 
F, S. 
1.30. 5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(1-((1-(2-fluorophenyl)ethyl)amino)-1-oxopropan-
2-yl)-1H-indole-2-carboxamide (37). Synthesized following general procedure A, starting from 40 and 
1-(2-fluorophenyl)ethanamine. Yield 70%, mp 200-202 °C (from ethanol). 1H NMR (400 MHz, 
DMSO-d6): δ 1.34-1.42 (m, 6H), 2.22-2.28 (m, 6H), 4.60-4.66 (m, 1H), 5.15-5.22 (m, 1H), 7.10-7.18 
(m, 2H), 7.23-7.44 (m, 4H), 7.51-7.56 (m, 1H), 7.67-7.68 (m, 2H), 7.80 (s, 1H), 8.57 (d, J = 10.2 Hz, 
1H, disappeared on treatment with D2O), 9.36 (d, J = 12.4 Hz, 1H, disappeared on treatment with D2O), 
13.04 ppm (br s, 1H, disappeared on treatment with D2O). 13C NMR (300 MHz, DMSO-d6,):  18.76, 
18.96, 21.09, 21.83, 43.02, 49.54, 112.19, 115.51, 115.77, 119.56, 124.06, 124.87, 125.45, 125.91, 
127.36, 127.63, 127.90, 129.03, 131.69, 131.86, 133.31, 135.32, 139.55, 142.67, 158.90, 161.47, 
170.81 ppm. IR: ν 1529, 1638, 2932, 3198 cm-1. Anal. (C28H27ClFN3O4S (556.05)) C, H, N, Cl, F, S.  
 
2. Enantiomers 
2.1. Enantioselective separations. Enantioselective HPLC analysis were performed by using 
stainless-steel Chiralpak IA (250 mm x 4.6 mm I.D. and 250 mm x 10 mm I.D.) and Chiralpak IC (250 
mm x 4.6 mm I.D. and 250 mm x 10 mm I.D.) (Daicel, Chemical Industries, Tokyo, Japan) columns. 
HPLC-grade solvents were used as supplied by Aldrich (Milan, Italy). The HPLC apparatus consisted 
of a Perkin Elmer (Norwalk, CT, USA) 200 lc pump equipped with a Rheodyne (Cotati, CA, USA) 
injector, a 1000 L sample loop, a HPLC Perkin Elmer oven and a Perkin Elmer 290 detector. The 
signal was acquired and processed by Clarity software.40 
 HPLC resolutions were carried out by using polysaccharide-based chiral stationary phases 
(CSPs). The CSP/eluent system and the corresponding chromatographic data for each compound 
analyzed are resumed as follows: 8: Chiralpak IA/ethanol-DEA 100:0.2, k1 = 0.67 (R), k2 = 1.03 (S), 
temp.: 40 °C; 23: Chiralpak IA/ethanol-DEA 100:0.2, k1 = 0.33 (R), k2 = 0.75 (S), temp.: 40 °C; 24: 
Chiralpak IC/ethyl acetate-methanol-DEA 100:0.2, k1 = 0.76 (S), k2 = 1.51 (R), temp.: 25 °C; 25: 
Chiralpak IC/n-hexane-ethanol-dichloromethane-DEA 40:15:45:0.3, k1 = 0.58 (R,S), k2 = 0.81 (S,R), k3 
= 1.20 (S,S), k4 = 2.72 (R,R), temp.: 25 °C; 31: Chiralpak IA/ethanol-dichloromethane-DEA 100:1:0.1, 
k1 = 0.40 (R), k2 = 1.05 (S), temp.: 40 °C; 33: Chiralpak IA/n-hexane-ethyl acetate-DEA 50:50:0.1, k1 = 
1.94 (S), k2 = 2.51 (R), temp.: 25 °C. k1 and k2 are the retention factors of the less retained enantiomer 
and the more retained enantiomer, respectively. 
 The CD spectra of (S)-8 obtained by stereospecific synthesis and the enantiomers of 23 isolated 
at semipreparative scale were dissolved in ethanol (concentration about 0.2 mg/ml) in a quartz cell (0.1 
cm-path length) at 25 °C and measured by using a Jasco41 Model J-700 spectropolarimeter in the 400-
200 nm spectral range. The spectra were average computed over three instrumental scans and the 
intensities were presented in terms of ellipticity values (mdeg).  
2.2. Absolute configuration assignment. The absolute configurations of the enantiomers of 8, 23, 24, 
31, 33 and four stereoisomers of 25 were empirically assigned by a combination of chemical 
correlation/enantioselective HPLC/circular dichroism methods. Commercially available (S)-
enantiomers of the amines were used as starting material for the stereospecific synthesis of the (S)-IAS 
derivatives. The coupling reaction between the chiral amine and the corresponding carboxylic acid did 
not affect the stereogenic center and the designed enantiomer retained its absolute configuration during 
the conversion. The stereochemical course of the reactions was monitored by the HPLC conditions 
described in the experimental section. 
 The ee values ranged from 60 to 99% with the only exception of 23, for which a complete 
racemization was observed. The stereochemical assignment of the enantiomers of 23 was obtained by 
comparing their CD spectra with those of the enantiomers of 8 of known stereochemistry (Figure 4S, 
Supporting Information). 
 
3. Molecular Modeling. All molecular modeling studies were performed on a MacPro dual 2.66 
GHz Xeon running Ubuntu 12. The images in the manuscript were created with PyMOL.42 The RTs 
structures were downloaded from the PDB website:43 WT RT, 2RF2;44 K103N RT, 3MED;45 Y181C 
RT, 1UWB.46 Hydrogen atoms were added to the protein using the Protonate #D option in Molecular 
Operating Environment (MOE) 2014.47 Ligand structures were built with MOE and minimized using 
the MMFF94x force field until a rmsd gradient of 0.05 kcal/(mol·Å) was reached. The docking 
simulations were performed using PLANTS.48 We set a binding lattice of 15 Å radius using all default 
settings used. Molecular dynamics was performed with the Amber 12 suite.49 The minimized structure 
was solvated in a periodic octahedron simulation box using TIP3P water molecules, providing a 
minimum of 10 Å of water between the protein surface and any periodic box edge. Ions were added to 
neutralize the charge of the total system. The water molecules and Cl- ions were energy-minimized 
keeping the coordinates of the protein-ligand complex fixed (1000 cycle), and then the whole system 
was minimized (5000 cycle). Following minimization, the entire system was heated to 298 K (20 ps). 
The production (50 ns) simulation was conducted at 298 K with constant pressure and periodic 
boundary condition. Shake bond length condition was used (ntc = 2). Production was carried out on 
GeForce gtx780 gpu. Compounds were parametrized by Antechamber50,51 using BCC charges. 
Trajectories analysis were carried out by cpptraj program.52 Molecular dynamics snapshots were 
obtained by computing the average for the latest 3500 steps and then was selected as representative step 
the one with the lowest RMSD versus computed average. Binding free energy were computed by 
sietraj.53,54 
 
4. Biological Assays 
4.1. Inhibition of HIV-induced cytopathicity. Biological activity of the compounds was tested in the 
lymphoid MT-4 cell line (received from the NIH AIDS Reagent Program) against the WT HIV-1 NL4-
3 strain and the different mutant HIV-1 strains, as described before.55 Briefly, MT-4 cells were infected 
with the appropriate HIV-1 strain (or mock-infected to determine cytotoxicity) in the presence of 
different drug concentrations. At day five post-infection, a tetrazolium-based colorimetric method 
(MTT method) was used to evaluate the number of viable cells. 
4.2. Enzymatic assay procedures. Chemicals. [3H]dTTP (40 Ci/mmol) was from Perkinelmer and 
unlabelled dNTP's from Promega. Perkinelmer was the supplier of the GF/C filters. All other reagents 
were of analytical grade and purchased from Sigma. Nucleic acid substrate. The homopolymer 
poly(rA) (Pharmacia) was mixed at weight ratios in nucleotides of 10:1, to the oligomer oligo(dT)12-18 
(Pharmacia) in 20 mM Tris-HCl (pH 8.0), containing 20 mM KCl and 1 mM EDTA, heated at 65 °C 
for 5 min and then slowly cooled at room temperature. Enzymatic assay. The coexpression vectors 
pUC12N/p66(His)/p51with the wild-type or the mutant forms of HIV-1 RT p66 were kindly provided 
by Dr. S. H. Hughes (NCI-Frederick Cancer Research and Development Center). Proteins were 
expressed in E. coli and purified as described.56 RNA-dependent DNA polymerase activity was assayed 
as follows: a final volume of 15 µL contained reaction buffer (50 mM Tris-HCl pH 7.5, 1 mM DTT, 
0.2 mg/mL BSA, 4% glycerol), 10% DMSO, 10 mM MgCl2, 0.5 µg of poly(rA)/oligo(dT)10:1 (0.3 µM 
3'-OH ends), 10 µM [3H]-dTTP (1Ci/mmol) and 2-4 nM RT. Reactions were incubated at 37 °C for the 
indicated time. 10 µL-Aliquots were then spotted on glass fiber filters GF/C which were immediately 
immersed in 5% ice-cold TCA. Filters were washed twice in 5% ice-cold TCA and once in ethanol for 
5 min, dried and acid-precipitable radioactivity was quantitated by scintillation counting. Reactions 
were performed under the conditions described for the HIV-1 RT RNA-dependent DNA polymerase 
activity assay. Incorporation of radioactive dTTP into poly(rA)/oligo(dT) at different substrate (nucleic 
acid or dTTP) concentrations was monitored in the presence of increasing fixed inhibitor dose was 
monitored, and data were then plotted according to equation 1 using Graphpad Prism 5.0 software 
 
ID50 = V= v/(1+([I]/ID50)) 
Equation 1. V: maximum velocity of the reaction; v: reaction velocity; [I]: inhibitor concentration; ID50: calculated 
inhibitor dose that conferred 50% enzymatic activity. 
 
 
4.3. Cell line and neuronal cultures. BV2 cells were maintained in culture in DMEM containing 
10% FBS. Cells were used up to passage 40. Primary hippocampal neuronal cultures were prepared 
from 0-2-day old (p0–p2) C57BL/6 mice. Briefly, after careful dissection from diencephalic structures, 
the meninges were removed and hippocampal tissues chopped and digested for 20 min at 37 °C in 
0.025% trypsin and Hank’s balanced salt solution (HBSS). Cells were washed twice with HBSS to 
remove the excess of trypsin, mechanically dissociated in minimal essential medium (MEM) with 
Earl’s Salts and GLUTAMAX supplemented with 10% dialyzed and heat inactivated FBS. Cells were 
plated at a density of 2 x 105 in the same medium on poly-L-lysine (100 µg/mL)-coated plastic 24-well 
dishes. After 2 h, the medium was replaced with serum- free Neurobasal/B27. Cells were kept at 37 °C 
in 5% CO2 for 11 days. By this method we obtained 60-70% neurons, 30-35% astrocytes, 4-8% 
microglia, as previously reported.57 Procedures were approved by the Italian Ministry of Health in 
accordance with the guidelines on the ethical use of animals from the European Community Council 
Directive of 22 September 2010 (2010/63/EU) 
4.4. Nitrite assay. NO production of BV2 cells was assessed by measuring nitrite accumulation in 
the culture medium by Griess Reagent Kit according to manifacturer instructions (Molecular Probes, 
MA, USA). The absorbance was measured at 570 nm in a spectrophotometric microplate reader 
(BioTek Instruments Inc, VT, USA).  
4.5. MTT cell viability assay. BV2 cell lines were seeded into multi-well plates and treated with 
vehicle  or 10, 102, 103 or 104 nM (R,S)-23 or EFV for 0-24-48 h. MTT (500 μg/mL) was added into 
each well for 2 h. DMSO was then added to stop the reaction and the produced formazan was measured 
at 570 nm in a spectrophotometric microplate reader (BioTek Instruments Inc, VT, USA). Viability of 
cells was expressed as % relative to 0 h. 
4.6. Excitotoxicity assay. Hippocampal cultures were treated with 100 M glutamate in Locke’s 
buffer containing NaCl (154 mM), KCl (5.6 mM), NaHCO3 (3.6 mM), HEPES (5 mM), CaCl2 (2.3 
mM), glucose (5.6 mM), glycine (10 mM) at pH 7.4 for 30 min in the presence or absence of (R,S)-23 
or EFV and then re-incubated in the conditioned culture medium for 18 h in the presence or absence of 
(R,S)-23 or EFV. To evaluate neuron viability, hippocampal neuronal cultures were treated with 
detergent-containing buffer (0.05% ethyl hexadecyl dimethylammonium bromide, 0.028% acetic acid, 
0.05% Triton X-100, 0.3 mM NaCl, 0.2 mM MgCl2 in PBS pH 7.4) and viable nuclei counted in a 
hemacytometer as described.58,59 
4.7. Real Time PCR. BV2 cells were treated with (R,S)-23 or EFV. After 24 h total RNA was 
extracted with Trizol reagent (Invitrogen, Italy), quantified and retro-transcripted using IScriptTM 
Reverse Transcription Supermix (Biorad, Italy). Real Time PCR (RT-PCR) was carried out in an I-
Cycler IQ Multicolor RT-PCR Detection System (Biorad, Italy) using SsoFast Eva Green Supermix 
(Biorad, Italy). The PCR protocol consisted of 40 cycles of denaturation at 95 °C for 30 s and 
annealing/extension at 58 °C for 30 s. The Ct values from each gene were normalized to the Ct value of 
GAPDH. Relative quantification was performed using the 2-ΔΔCt method and expressed as fold increase. 
Primer sequences are: gapdh: fw TCGTCCCGTAGACAAAATGG, rev 
TTGAGGTCAATGAAGGGGTC; inos: fw, CATCGACCCGTCCACAGTAT, rev 
CAGAGGGGTAGGCTTGTCTC; cd86: fw, AGAACTTACGGAAGCACCCA, rev 
GGCAGATATGCAGTCCCATT; cd163: fw, TCTGGCTTGACAGCGTTTC, rev, 
TGTGTTTGTTGCCTGGATT; fizz1: fw, CCAATCCAGCTAACTATCCCTCC, rev, 
ACCCAGTAGCAGTCATCCCA. 
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Figure 1S. Left panel: trajectories snapshots of (R)-8 and (R)-23 versus Y181C RT. Right panel: trajectories snapshots of 
(S)-8 with (S)-23 versus Y181C RT. Residues involved in interactions are reported as lines. Mutated residue is depicted as 
stick. RT is shown as cartoon. H-bonds are depicted as yellow dotted lines. 
 
 
  
 
     
 
Figure 2S. Compound 23 and EFV treatments reduce NO release induced by LPS on BV2 cells. BV2 cells were treated 
with 10 nM, 102 nM, 103 nM or 104 nM concentrations of 23 or EFV in the presence or absence of 50 ng/mL LPS for 24 h. 
NO release was measured by Greiss reaction. Data are expressed as M. N=3; *p<0,05 vs CTL by Kruskal-Wallis One Way 
Analysis of Variance (Dunn’s method). 
 
 
 
 
 
 
 
      
 
Figure 3S. Compound 23 and EFV treatments do not modify BV2 cell proliferation. BV2 cells were treated with 10 nM, 
102 nM, 103 nM and 104 nM of 23 or EFV for 0, 24 and 48 h. Proliferation rate was measured by MTT assay. Data are 
expressed as % vs vehicle at 0h. N=3.   
 
 
  
Figure 4S.  Comparison of the CD spectra of (S)-8 and the enantiomers of 23 recorded in ethanol. 
 
 
 
 
 
Figure 5S. Enantiomeric purity of the enantiomers of 8 separated at semipreparative scale. 
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Figure 6S. Enantiomeric purity of the enantiomers of 23 separated at semipreparative scale. 
 
 
 
Figure 7S. Enantiomeric purity of the enantiomers of 24 separated at semipreparative scale. 
 
 
 
Figure 8S. Enantiomeric purity of the enantiomers of 25 separated at semipreparative scale. 
 
 
 
Figure 9S. Enantiomeric purity of the enantiomers of 31 separated at semipreparative scale. 
 
 
 Figure 10S. Enantiomeric purity of the enantiomers of 33 separated at semipreparative scale. 
 
  
Table 1S. In silico physicochemical properties of 9-22, 24 and 26-37. 
Cmpd LogPa TPSAb H-bond Acc.c 
H-bond 
Don.d MW
e
 QPP Cacof QPP MDCKg 
9 2.70 100.55 4 2 456.94 1359.11 1719.66 
10 4.75 87.41 3 2 527.46 1390.83 4295.93 
11 3.71 96.64 5 2 500.97 1702.21 3131.21 
12 4.62 87.41 5 2 502.96 1430.99 5407.89 
13 3.99 87.41 4 2 484.97 1184.16 2460.85 
14 4.42 87.41 5 2 488.94 1093.77 3640.43 
15 2.00 124.09 5 2 478.95 148.66 153.92 
16 2.00 124.09 5 2 478.95 131.72 134.9 
17 3.14 113.43 3 3 467.97 275.47 299.61 
18 2.97 142.11 4 4 507.99 74.95 74.46 
19 3.22 116.09 4 3 492.98 378.62 431.52 
20 3.01 116.51 4 3 524.04 305.67 603.56 
21 3.21 116.51 4 3 538.08 555.98 882.22 
22 1.82 129.40 5 3 511.00 140.77 269.22 
24 2.03 129.40 5 3 525.03 214.84 388.32 
26 2.65 144.75 4 3 530.07 235.21 725.6 
27 2.85 144.75 4 3 544.10 347.91 1050.92 
28 1.50 180.15 7 3 573.03 301.56 943.23 
29 1.70 180.15 7 3 587.05 190.26 201.45 
30 1.25 141.29 6 3 511.99 135.68 258.24 
31 1.45 142.29 6 3 526.02 176.09 279.78 
32 1.65 129.65 5 3 499.98 197.37 372.13 
33 1.86 129.65 5 3 514.00 277.73 554.97 
34 3.18 116.51 5 3 528.00 240.43 688.91 
35 3.38 116.51 5 3 542.03 464.70 1224.57 
36 3.38 116.51 5 3 542.03 400.35 860.26 
37 3.57 116.51 5 3 556.06 627.59 1446.23 
Physicochemical properties predicted by SwissADME:1S aOctanol-water partition coefficient predictor by 
topological method implemented from Moriguchi;2S,3S bMolecular polar surface area: this parameter 
correlates with human intestinal absorption (<140).4S cNumber of H-bond acceptors; dNumber of H-bond 
donors; eMolecular Weight. Physicochemical properties predicted by QikProp:5S fQPP Caco - Apparent 
Caco-2 permeability (nm/sec) (<25 poor, >500 great); gQPP MDCK - Apparent MDCK permeability 
(nm/sec) (<25 poor, >500 great). 
 
  
Table 2S. Elemental analyses of compounds 8-37. 
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compd Calculated (%) Found (%) 
8 C, 61.91; H, 4.57; Cl, 7.31; F, 3.92; N, 5.78; S, 6.61 C, 61.76; H, 4.52; Cl, 7.11; F, 3.80; N, 5.62; S, 6.42 
9 C, 60.46; H, 4.63; Cl, 7.76; N, 6.13; S, 7.02 C, 60.25; H, 4.59; Cl, 7.62; N, 6.02; S, 6.88 
10 C, 61.48; H, 4.59; Cl, 13.44; N, 5.31; S, 6.08 C, 61.37; H, 4.54; Cl, 13.36; N, 5.22; S, 5.90 
11 C, 59.94; H, 4.43; Cl, 7.08; F, 3.79; N, 5.59; S, 6.40 C, 59.85; H, 4.39; Cl, 6.91; F, 3.65; N, 5.48; S, 6.32 
12 C, 59.70; H, 4.21; Cl, 7.05; F, 7.55; N, 5.57; S, 6.38 C, 59.59; H, 4.17; Cl, 6.88; F, 7.37; N, 5.68; S, 6.19 
13 C, 61.91; H, 4.40; Cl, 7.31; F, 3.92; N, 5.78; S, 6.61 C, 61.84; H, 4.44; Cl, 7.19; F, 3.75; N, 5.69; S, 6.48 
14 C, 58.96; H, 3.92; Cl, 7.25; F, 7.77; N, 5.73; S, 6.56 C, 58.68; H, 3.88; Cl, 7.13; F, 7.58; N, 5.61; S, 6.88 
15 C, 59.42; H, 3.69; Cl, 7.63; N, 12.05; S, 6.90 C, 59.26; H, 3.61; Cl, 7.40; N, 11.95; S, 6.78 
16 C, 59.42; H, 3.69; Cl, 7.63; N, 12.05; S, 6.90 C, 59.34; H, 3.61; Cl, 7.51; N, 11.88; S, 6.71 
17 C, 61.60; H, 4.74; Cl, 7.58; N, 8.98; S, 6.85 C, 61.50; H, 4.68; Cl, 7.48; N, 8.81; S, 6.78 
18 C, 59.11; H, 4.37; Cl, 6.98; N, 13.79; S, 6.31 C, 58.89; H, 4.32; Cl, 6.88; N, 13.68; S, 6.20 
19 C, 60.51; H, 4.46; Cl, 7.24; N, 11.44; S, 6.55 C, 60.42; H, 4.42; Cl, 7.13; N, 11.29; S, 6.31 
20 C, 61.88; H, 5.00; Cl, 6.77; N, 8.02; S, 6.12 C, 61.73; H, 4.98; Cl, 6.64; N, 7.92; S, 5.97 
21 C, 62.50; H, 5.25; Cl, 6.59; N, 7.81; S, 5.96 C, 62.42; H, 5.16; Cl, 6.42; N, 7.70; S, 5.85 
22 C, 58.76; H, 4.54; Cl, 6.94; N, 10.96; S, 6.28 C, 58.59; H, 4.48; Cl, 6.78; N, 10.82; S, 6.07 
23 C, 59.48; H, 4.80; Cl, 6.75; N, 10.67; S, 6.11 C, 59.31; H, 4.72; Cl, 6.69; N, 10.58; S, 5.93 
24 C, 59.48; H, 4.80; Cl, 6.75; N, 10.67; S, 6.11 C, 59.26; H, 4.71; Cl, 6.66; N, 10.39; S, 5.90 
25 C, 60.16; H, 5.05; Cl, 6.58; N, 10.39; S, 5.95 C, 59.98; H, 4.99; Cl, 6.42; N, 10.25; S, 5.72 
26 C, 56.65; H, 4.56; Cl, 6.69; N, 7.93; S, 12.10 C, 56.51; H, 4.49; Cl, 6.45; N, 7.81; S, 11.95 
27 C, 57.40; H, 4.82; Cl, 6.52; N, 7.72; S, 11.79 C, 57.27; H, 4.80; Cl, 6.48; N, 7.52; S, 11.54 
28 C, 52.40; H, 4.40; Cl, 6.19; N, 14.67; S, 5.60 C, 52.12; H, 4.34; Cl, 5.98; N, 14.42;  S, 5.46 
29 C, 53.19; H, 4.64; Cl, 6.04; N, 14.32; S, 5.46 C, 53.04; H, 4.58; Cl, 5.89; N, 14.15; S, 5.21 
30 C, 56.30; H, 4.33; Cl, 6.92; N, 13.68; S, 6.26 C, 56.21; H, 4.29; Cl, 6.78; N, 13.38; S, 6.07 
31 C, 57.08; H, 4.60; Cl, 6.74; N, 13.31; S, 6.10 C, 56.91; H, 4.52; Cl, 6.51; N, 13.05; S, 5.88 
32 C, 57.66; H, 4.44; Cl, 7.09; N, 8.40; S, 6.41 C, 57.48; H, 4.37; Cl, 6.95; N, 8.21; S, 6.25 
33 C, 58.42; H, 4.71; Cl, 6.90; N, 8.18; S, 6.24 C, 58.25; H, 4.68; Cl, 6.75; N, 7.92; S, 6.11 
34 C, 59.14; H, 4.39; Cl, 6.71; F, 3.60; N, 7.96; S, 6.07 C, 58.92; H, 4.28; Cl, 6.64; F, 3.49; N, 7.72; S, 5.87 
35 C, 59.83; H, 4.65; Cl, 6.54; F, 3.51; N, 7.75; S, 5.92 C, 59.55; H, 4.59; Cl, 6.28; F, 3.42; N, 7.51; S, 5.70 
36 C, 59.83; H, 4.65; Cl, 6.54; F, 3.51; N, 7.75; S, 5.92 C, 59.61; H, 4.54; Cl, 6.37; F, 3.40; N, 7.49; S, 5.78 
37 C, 60.48; H, 4.89; Cl, 6.38; F, 3.42; N, 7.56; S, 5.77 C, 60.37; H, 4.82; Cl, 6.25; F, 3.28; N, 7.38; S, 5.41 
